US20240034812A1 - Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma - Google Patents
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma Download PDFInfo
- Publication number
- US20240034812A1 US20240034812A1 US18/025,203 US202118025203A US2024034812A1 US 20240034812 A1 US20240034812 A1 US 20240034812A1 US 202118025203 A US202118025203 A US 202118025203A US 2024034812 A1 US2024034812 A1 US 2024034812A1
- Authority
- US
- United States
- Prior art keywords
- administered
- day
- dose
- cycles
- bispecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 title claims abstract description 75
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 title claims abstract description 75
- 238000002648 combination therapy Methods 0.000 title description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims abstract description 265
- 238000000034 method Methods 0.000 claims abstract description 200
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims abstract description 191
- 229960004618 prednisone Drugs 0.000 claims abstract description 185
- 229960004641 rituximab Drugs 0.000 claims abstract description 137
- 229960004679 doxorubicin Drugs 0.000 claims abstract description 133
- 229960004528 vincristine Drugs 0.000 claims abstract description 133
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims abstract description 133
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims abstract description 132
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims abstract description 129
- 229960004397 cyclophosphamide Drugs 0.000 claims abstract description 122
- 229940013179 epcoritamab Drugs 0.000 claims description 127
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 93
- 230000004044 response Effects 0.000 claims description 62
- 230000037452 priming Effects 0.000 claims description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 39
- 201000010099 disease Diseases 0.000 claims description 37
- 238000002560 therapeutic procedure Methods 0.000 claims description 34
- 229960000106 biosimilars Drugs 0.000 claims description 27
- 208000037821 progressive disease Diseases 0.000 claims description 22
- 201000003444 follicular lymphoma Diseases 0.000 claims description 11
- 230000036961 partial effect Effects 0.000 claims description 11
- 230000002503 metabolic effect Effects 0.000 claims description 5
- 231100000402 unacceptable toxicity Toxicity 0.000 claims description 5
- 238000011282 treatment Methods 0.000 abstract description 76
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 abstract description 36
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 abstract description 35
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 abstract description 29
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 abstract description 29
- 206010052015 cytokine release syndrome Diseases 0.000 description 144
- 238000001990 intravenous administration Methods 0.000 description 100
- 238000011321 prophylaxis Methods 0.000 description 95
- 235000001014 amino acid Nutrition 0.000 description 56
- 239000000427 antigen Substances 0.000 description 54
- 102000036639 antigens Human genes 0.000 description 54
- 108091007433 antigens Proteins 0.000 description 54
- 238000009101 premedication Methods 0.000 description 49
- 150000001413 amino acids Chemical class 0.000 description 48
- 239000003246 corticosteroid Substances 0.000 description 48
- -1 diphenhydramine Chemical compound 0.000 description 46
- 239000000543 intermediate Substances 0.000 description 46
- 230000003902 lesion Effects 0.000 description 45
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 38
- 230000003442 weekly effect Effects 0.000 description 38
- 229960003989 tocilizumab Drugs 0.000 description 37
- 239000000047 product Substances 0.000 description 34
- 206010028980 Neoplasm Diseases 0.000 description 32
- 230000000875 corresponding effect Effects 0.000 description 32
- 238000006467 substitution reaction Methods 0.000 description 28
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 26
- 206010045170 Tumour lysis syndrome Diseases 0.000 description 25
- 208000010380 tumor lysis syndrome Diseases 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 22
- 229960005489 paracetamol Drugs 0.000 description 21
- 238000007920 subcutaneous administration Methods 0.000 description 21
- 238000001574 biopsy Methods 0.000 description 20
- 210000001185 bone marrow Anatomy 0.000 description 20
- 239000003814 drug Substances 0.000 description 20
- 238000002347 injection Methods 0.000 description 20
- 239000007924 injection Substances 0.000 description 20
- 229960005205 prednisolone Drugs 0.000 description 20
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 20
- 150000003431 steroids Chemical class 0.000 description 19
- 206010025323 Lymphomas Diseases 0.000 description 18
- 101100495232 Homo sapiens MS4A1 gene Proteins 0.000 description 17
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 17
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 17
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 17
- 229960000520 diphenhydramine Drugs 0.000 description 17
- 229940079593 drug Drugs 0.000 description 17
- 238000012216 screening Methods 0.000 description 17
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 16
- 230000001754 anti-pyretic effect Effects 0.000 description 16
- 239000002221 antipyretic Substances 0.000 description 16
- 229940090044 injection Drugs 0.000 description 16
- 239000008194 pharmaceutical composition Substances 0.000 description 16
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 15
- 206010037660 Pyrexia Diseases 0.000 description 15
- 239000000739 antihistaminic agent Substances 0.000 description 15
- 230000000977 initiatory effect Effects 0.000 description 15
- 230000004048 modification Effects 0.000 description 15
- 238000012986 modification Methods 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 15
- 210000001744 T-lymphocyte Anatomy 0.000 description 14
- 230000035772 mutation Effects 0.000 description 14
- 206010061818 Disease progression Diseases 0.000 description 13
- 108060003951 Immunoglobulin Proteins 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 230000005750 disease progression Effects 0.000 description 13
- 102000018358 immunoglobulin Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 208000007660 Residual Neoplasm Diseases 0.000 description 12
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 12
- 230000001387 anti-histamine Effects 0.000 description 12
- 229960003957 dexamethasone Drugs 0.000 description 12
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 206010021143 Hypoxia Diseases 0.000 description 11
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 10
- 208000001953 Hypotension Diseases 0.000 description 10
- 229940124572 antihypotensive agent Drugs 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 230000036543 hypotension Effects 0.000 description 10
- 230000007954 hypoxia Effects 0.000 description 10
- 239000005526 vasoconstrictor agent Substances 0.000 description 10
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 9
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 9
- 239000003638 chemical reducing agent Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 238000002595 magnetic resonance imaging Methods 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 208000004235 neutropenia Diseases 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 229960003323 siltuximab Drugs 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 229940116269 uric acid Drugs 0.000 description 9
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 8
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 8
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 8
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 229960004238 anakinra Drugs 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 229960001334 corticosteroids Drugs 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 229960004584 methylprednisolone Drugs 0.000 description 8
- 229960000424 rasburicase Drugs 0.000 description 8
- 108010084837 rasburicase Proteins 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000002411 adverse Effects 0.000 description 7
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 7
- 229960003459 allopurinol Drugs 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 230000003285 pharmacodynamic effect Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 208000010378 Pulmonary Embolism Diseases 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000002565 electrocardiography Methods 0.000 description 6
- 210000004602 germ cell Anatomy 0.000 description 6
- 231100000226 haematotoxicity Toxicity 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000003908 liver function Effects 0.000 description 6
- 238000007726 management method Methods 0.000 description 6
- 238000009120 supportive therapy Methods 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 238000011269 treatment regimen Methods 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 206010051055 Deep vein thrombosis Diseases 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 241000282567 Macaca fascicularis Species 0.000 description 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 5
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 5
- 108010004977 Vasopressins Proteins 0.000 description 5
- 102000002852 Vasopressins Human genes 0.000 description 5
- 206010047249 Venous thrombosis Diseases 0.000 description 5
- 208000007502 anemia Diseases 0.000 description 5
- 229940125716 antipyretic agent Drugs 0.000 description 5
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 5
- 238000002591 computed tomography Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 150000004677 hydrates Chemical class 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229940068968 polysorbate 80 Drugs 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229960003726 vasopressin Drugs 0.000 description 5
- AQTQHPDCURKLKT-PNYVAJAMSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-PNYVAJAMSA-N 0.000 description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 4
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 4
- 108091012583 BCL2 Proteins 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 4
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 4
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 230000010782 T cell mediated cytotoxicity Effects 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 206010044221 Toxic encephalopathy Diseases 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 208000021173 high grade B-cell lymphoma Diseases 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000007135 neurotoxicity Effects 0.000 description 4
- 229960002748 norepinephrine Drugs 0.000 description 4
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 4
- 208000033808 peripheral neuropathy Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010043554 thrombocytopenia Diseases 0.000 description 4
- 238000002627 tracheal intubation Methods 0.000 description 4
- 230000005945 translocation Effects 0.000 description 4
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091008875 B cell receptors Proteins 0.000 description 3
- 206010065553 Bone marrow failure Diseases 0.000 description 3
- 208000020446 Cardiac disease Diseases 0.000 description 3
- 206010048610 Cardiotoxicity Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 208000002633 Febrile Neutropenia Diseases 0.000 description 3
- 102000009490 IgG Receptors Human genes 0.000 description 3
- 108010073807 IgG Receptors Proteins 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 206010029350 Neurotoxicity Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010041660 Splenomegaly Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000003092 anti-cytokine Effects 0.000 description 3
- 230000000690 anti-lymphoma Effects 0.000 description 3
- 229940125715 antihistaminic agent Drugs 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 231100000259 cardiotoxicity Toxicity 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000009093 first-line therapy Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 201000002364 leukopenia Diseases 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005399 mechanical ventilation Methods 0.000 description 3
- 230000000116 mitigating effect Effects 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- 231100000228 neurotoxicity Toxicity 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 230000000153 supplemental effect Effects 0.000 description 3
- 230000003319 supportive effect Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000024883 vasodilation Effects 0.000 description 3
- 238000009423 ventilation Methods 0.000 description 3
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 2
- 206010002388 Angina unstable Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 102000053028 CD36 Antigens Human genes 0.000 description 2
- 108010045374 CD36 Antigens Proteins 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 230000009946 DNA mutation Effects 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 206010028116 Mucosal inflammation Diseases 0.000 description 2
- 201000010927 Mucositis Diseases 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 2
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- 208000007814 Unstable Angina Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 239000008228 bacteriostatic water for injection Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 210000001370 mediastinum Anatomy 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 201000000317 pneumocystosis Diseases 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 229940093609 tricaprylin Drugs 0.000 description 2
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 2
- 229960002110 vincristine sulfate Drugs 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
- WITKSCOBOCOGSC-UHFFFAOYSA-N 2-dodecanoyloxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCCCC WITKSCOBOCOGSC-UHFFFAOYSA-N 0.000 description 1
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 201000002882 Agraphia Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000032862 Clinical Deterioration Diseases 0.000 description 1
- 206010010305 Confusional state Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 206010011793 Cystitis haemorrhagic Diseases 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010063045 Effusion Diseases 0.000 description 1
- 241000277306 Esocidae Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 description 1
- 208000009139 Gilbert Disease Diseases 0.000 description 1
- 208000022412 Gilbert syndrome Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000007521 HIV Seropositivity Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
- 101000777658 Homo sapiens Platelet glycoprotein 4 Proteins 0.000 description 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- 206010058819 Hyperalbuminaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 206010065048 Latent tuberculosis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 238000011789 NOD SCID mouse Methods 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000007125 Neurotoxicity Syndromes Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 206010061334 Partial seizures Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 206010040026 Sensory disturbance Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 208000007888 Sinus Tachycardia Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010045169 Tumour flare Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229940119059 actemra Drugs 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000012443 analytical study Methods 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000000947 anti-immunosuppressive effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 208000027119 bilirubin metabolic disease Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 231100000313 clinical toxicology Toxicity 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000004209 confusion Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229940108605 cyclophosphamide injection Drugs 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229940027008 deltasone Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000276 dose-dependent cytotoxicity Toxicity 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011985 exploratory data analysis Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000027950 fever generation Effects 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 201000002802 hemorrhagic cystitis Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000051522 human CD36 Human genes 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 102000054751 human RUNX1T1 Human genes 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 208000036796 hyperbilirubinemia Diseases 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 208000008384 ileus Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940124622 immune-modulator drug Drugs 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 230000004904 long-term response Effects 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000013439 planning Methods 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000030279 prolonged fever Diseases 0.000 description 1
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000007409 radiographic assessment Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 229940020549 rayos Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 208000020352 skin basal cell carcinoma Diseases 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960000999 sodium citrate dihydrate Drugs 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 229940083608 sodium hydroxide Drugs 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 208000014794 superficial urinary bladder carcinoma Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- LZPBKINTWROMEA-UHFFFAOYSA-N tetracene-5,12-dione Chemical compound C1=CC=C2C=C3C(=O)C4=CC=CC=C4C(=O)C3=CC2=C1 LZPBKINTWROMEA-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000155 toxicity by organ Toxicity 0.000 description 1
- 230000007675 toxicity by organ Effects 0.000 description 1
- 230000014723 transformation of host cell by virus Effects 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 208000021758 very high fever Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000009528 vital sign measurement Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Definitions
- the present invention relates to bispecific antibodies targeting both CD3 and CD20 and the use of such antibodies in combination with a standard of care R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) regimen for the treatment of diffuse large B-cell lymphoma (DLBCL), for example, previously untreated high-risk DLBCL.
- R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone
- DLBCL diffuse large B-cell lymphoma
- Advantageous treatment regimens are also provided.
- DLBCL is the most common non-Hodgkin lymphoma (NHL), and the standard first-line therapy is R-CHOP.
- the cure rate of this combination for the overall population of newly-diagnosed DLBCL is between 60% and 70% (Sehn et al., Blood 2007; 109:1867-61). Attempts to improve upon outcomes of first-line therapy, including intensification of dose and addition of other agents to intensify the regimen, have failed to provide sufficient evidence to alter standard of care.
- IPI International Prognostic Index
- R-IPI Revised-IPI
- DLBCL a bispecific antibody which binds to CD3 and CD20 in combination with a standard of care R-CHOP regimen, in particular, advantageous clinical treatment regimens.
- previously untreated DLBCL e.g., DLBCL with high-risk features (e.g., IPI or R-IPI ⁇ 3)
- a bispecific antibody which binds to CD3 and CD20 in combination with a standard of care R-CHOP regimen, in particular, advantageous clinical treatment regimens.
- a method of treating diffuse large B-cell lymphoma (DLBCL) in a human subject comprising administering to the subject the combination of epcoritamab with R-CHOP, e.g., the method comprising administering to the subject an effective amount of (a) rituximab, (b) cyclophosphamide, (c) doxorubicin, (d) vincristine, (e) prednisone, and (f) epcoritamab.
- a method of treating diffuse large B-cell lymphoma (DLBCL) in a human subject comprising administering to the subject a bispecific antibody and an effective amount of (a) rituximab, (b) cyclophosphamide, (c) doxorubicin, (d) vincristine, (e) prednisone, wherein the bispecific antibody comprises:
- the bispecific antibody is administered at a dose of (or a dose of about) 24 mg. In some embodiments, the bispecific antibody is administered at a dose of (or a dose of about) 48 mg.
- the bispecific antibody is administered once every week at a dose of 24 mg or 48 mg (weekly administration/dose), e.g., for three and one-third 21-day cycles (i.e., day 15 of cycle 1 and days 1, 8, and 15 of cycles 2-4).
- the bispecific antibody is administered once every three weeks after the weekly administration, e.g., for two or four 21-day cycles.
- the bispecific antibody is administered once every four weeks after the administration once every three weeks in 28-day cycles, e.g., for up to one year total duration of treatment with the bispecific antibody from initiation of R-CHOP (i.e., from cycle 1).
- a priming dose (e.g., 0.16 mg or about 0.16 mg) of the bispecific antibody is administered two weeks prior to administering the first weekly dose of 24 mg or 48 mg.
- an intermediate dose (e.g., 0.8 mg or about 0.8 mg) of the bispecific antibody is administered.
- the priming dose is administered one week before the intermediate dose, and the intermediate dose is administered one week before the first weekly dose of 24 mg or 48 mg.
- rituximab is administered in a 21-day cycle once every three weeks, e.g., for six or eight 21-day cycles. In some embodiments, rituximab is administered at a dose of 375 mg/m 2 .
- cyclophosphamide is administered in a 21-day cycle once every three weeks, e.g., for six or eight 21-day cycles. In some embodiments, cyclophosphamide is administered at a dose of 750 mg/m 2 .
- doxorubicin is administered in a 21-day cycle once every three weeks, e.g., for six or eight 21-day cycles. In some embodiments, doxorubicin is administered at a dose of 50 mg/m 2 .
- vincristine is administered in a 21-day cycle once every three weeks, e.g., for six or eight 21-day cycles. In some embodiments, vincristine is administered at a dose of 1.4 mg/m 2 .
- prednisone is administered once a day from day 1 to day 5 of the 21-day cycles, e.g., for six or eight 21-day cycles. In some embodiments, prednisone is administered at a dose of 100 mg/day.
- rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, and the bispecific antibody are administered on the same day (e.g., on day 1 of cycles 1-6 or day 1 of cycles 1-8), e.g., as shown in Table 2.
- administration is performed in 21-day cycles, wherein
- administration is performed in 21-day cycles, wherein
- the bispecific antibody is administered once every four weeks in 28-day cycles from cycle 7, wherein the bispecific antibody is administered on day 1 of each cycle.
- administration is performed in 21-day cycles, wherein
- administration is performed in 21-day cycles, wherein
- the bispecific antibody is administered once every four weeks in 28-day cycles from cycle 9, wherein the bispecific antibody is administered on day 1 of each cycle.
- the bispecific antibody is administered subcutaneously.
- rituximab is administered intravenously.
- cyclophosphamide is administered intravenously.
- doxorubicin is administered intravenously.
- vincristine is administered intravenously.
- prednisone is administered intravenously or orally.
- the bispecific antibody, rituximab, cyclophosphamide, doxorubicin, and vincristine are administered sequentially. For example, if administered on the same day, prednisone is administered first, rituximab is administered second, cyclophosphamide is administered third, doxorubicin is administered fourth, vincristine is administered fifth, and the bispecific antibody is administered last.
- the DLBCL is double-hit or triple-hit DLBCL. In some embodiments, the DLBCL is follicular lymphoma Grade 3B. In some embodiments, the subject has an International Prognostic Index (IPI) score or Revised IPI score ⁇ 3.
- IPI International Prognostic Index
- the subject is treated with prophylaxis for cytokine release syndrome (CRS).
- the prophylaxis comprises administering a corticosteroid (e.g., prednisone at a dose of, e.g., 100 mg/day or equivalent thereof, including oral dose) on, for example, the same day as the bispecific antibody.
- the corticosteroid is further administered on the second, third, and fourth days after administering the bispecific antibody.
- a corticosteroid such as prednisone or its equivalent may be administered for CRS prophylaxis on days for which the bispecific antibody is administered but R-CHOP is not administered (i.e., prednisone or its equivalent is administered on days 8-11 and 15-18 of the first 21-day cycle, and optionally on days 8-11 and 15-18 of the second 21-day cycle (or later cycles) if, e.g., CRS >Grade 1 remains at the end of the previous cycle).
- prednisone from R-CHOP is administered more than 120 minutes before administration of the bispecific antibody, then the subject is administered prednisone or an equivalent as CRS prophylaxis about 30-120 minutes prior to administration of the bispecific antibody.
- the subject is administered premedication, such as antihistamine (e.g., diphenhydramine, intravenously or orally at a dose of, e.g., 50 mg or equivalent thereof) and/or antipyretic (e.g., acetaminophen at a dose of, e.g., 650-1000 mg), to reduce reactions to injections.
- premedication such as antihistamine (e.g., diphenhydramine, intravenously or orally at a dose of, e.g., 50 mg or equivalent thereof) and/or antipyretic (e.g., acetaminophen at a dose of, e.g., 650-1000 mg), to reduce reactions to injections.
- premedication is administered on the same day as the bispecific antibody.
- the prophylaxis and premedication are administered in cycle 1 and start of cycle 2 of the 21-day cycles (i.e., together with the first dose of the bispecific antibody on day 1 in cycle 2).
- the prophylaxis is administered during the second and third administrations of the bispecific antibody during cycle 2 of the 21-day cycles when the subject experiences CRS greater than grade 1 after the first administration of the bispecific antibody in cycle 2 of the 21-day cycles.
- the prophylaxis is continued in a subsequent cycle, when in the last administration of the bispecific antibody of the previous cycle, the subject experiences CRS greater than grade 1.
- the prophylaxis and premedication are administered during cycle 2 of the 21-day cycles.
- the prophylaxis and premedication are administered during subsequent cycles.
- the subject is administered antibiotics if the subject develops Grade 1 CRS. In some embodiments, the subject is administered a vasopressor if the subject develops Grade 2 or Grade 3 CRS. In some embodiments, the subject is administered at least two vasopressors if the subject develops Grade 4 CRS.
- the subject is administered tocilizumab if the subject develops Grade 2, Grade 3, or Grade 4 CRS.
- the subject is further administered a steroid (e.g., dexamethasone or methylprednisolone).
- tocilizumab is switched to an anti-IL-6 antibody (e.g., siltuximab) or an IL-1R antagonist (e.g., anakinra) if the subject is refractory to tocilizumab.
- an anti-IL-6 antibody e.g., siltuximab
- an IL-1R antagonist e.g., anakinra
- the subject is administered prophylaxis for tumor lysis syndrome (TLS).
- the prophylaxis for TLS comprises administering one or more uric acid reducing agents prior to administration of the bispecific antibody.
- rasburicase and/or allopurinol is administered as the uric acid reducing agent.
- supportive therapy such as rasburicase, may be used.
- the subject treated with the methods described herein achieves a complete response, a partial response, or stable disease, e.g., as defined by the Lugano criteria or LYRIC.
- the first antigen-binding region of the bispecific antibody comprises VHCDR1, VHCDR2, and VHCDR3 comprising the amino acid sequences set forth in SEQ ID NOs: 1, 2, and 3, respectively, and VLCDR1, VLCDR2, and VLCDR3 comprising the amino acid sequences set forth in SEQ ID NO: 4, the sequence GTN, and SEQ ID NO: 5, respectively; and the second antigen-binding region comprises VHCDR1, VHCDR2, and VHCDR3 comprising the amino acid sequences set forth in SEQ ID NOs: 8, 9, and 10, respectively, and VLCDR1, VLCDR2, and VLCDR3 comprising the amino acid sequences set forth in SEQ ID NO: 11, the sequence DAS, and SEQ ID NO: 12, respectively.
- the first antigen-binding region of the bispecific antibody comprises a VH region comprising the amino acid sequence of SEQ ID NO: 6, and the VL region comprising the amino acid sequence of SEQ ID NO: 7; and the second antigen-binding region comprises a VH region comprising the amino acid sequence of SEQ ID NO: 13, and the VL region comprising the amino acid sequence of SEQ ID NO: 14.
- the first binding arm of the bispecific antibody is derived from a humanized antibody, preferably from a full-length IgG1, ⁇ (lambda) antibody (e.g., SEQ ID NO: 22).
- the second binding arm of the bispecific antibody is derived from a human antibody, preferably from a full-length IgG1, ⁇ (kappa) antibody (e.g., SEQ ID NO: 23).
- the bispecific antibody is a full-length antibody with a human IgG1 constant region.
- the bispecific antibody comprises an inert Fc region, for example, an Fc region in which the amino acids in the positions corresponding to positions L234, L235, and D265 in the human IgG1 heavy chain constant region of SEQ ID NO: 15 are F, E, and A, respectively.
- the bispecific antibody comprises substitutions which promote bispecific antibody formation, for example, wherein in the first heavy chain, the amino acid in the position corresponding to F405 in the human IgG1 heavy chain constant region of SEQ ID NO: 15 is L, and wherein in the second heavy chain, the amino acid in the position corresponding to K409 in the human IgG1 heavy chain constant region of SEQ ID NO: 15 is R, or vice versa.
- the bispecific antibody has both an inert Fc region (e.g., substitutions at L234, L235, and D265 (e.g., L234F, L235E, and D265A)) and substitutions which promote bispecific antibody formation (e.g., F405L and K409R).
- the bispecific antibody comprises heavy chain constant regions comprising the amino acid sequences of SEQ ID NOs: 19 and 20.
- the bispecific antibody comprises a first heavy chain and a first light chain comprising (or consisting of) the amino acid sequences set forth in SEQ ID NOs: 24 and 25, respectively, and a second heavy chain and a second light chain comprising (or consisting of) the amino acid sequences set forth in SEQ ID NOs: 26 and 27, respectively.
- the bispecific antibody is epcoritamab, or a biosimilar thereof.
- FIGS. 1 A- 1 D are graphs showing the minimal effects of CHOP components on DuoBody CD3xCD20-induced T-cell-mediated cytotoxicity.
- FIG. 1 A DuoBody CD3xCD20+cyclophosphamide
- FIG. 1 B DuoBody CD3xCD20+doxorubicin
- FIG. 1 C DuoBody CD3xCD20+vincristine
- FIG. 1 D DuoBody CD3xCD20+prednisone.
- Left panels show DuoBody CD3xCD20 dose-response curves for one representative donor.
- Right panels show the results for 4 donors, at 333 ng/mL DuoBody CD3xCD20.
- FIG. 2 is a schematic of the overall clinical trial design.
- FIG. 3 is a schematic of the dose escalation design.
- immunoglobulin refers to a class of structurally related glycoproteins consisting of two pairs of polypeptide chains, one pair of light (L) low molecular weight chains and one pair of heavy (H) chains, all four inter-connected by disulfide bonds.
- L light
- H heavy
- each heavy chain typically is comprised of a heavy chain variable region (abbreviated herein as VH or V H ) and a heavy chain constant region (abbreviated herein as CH or C H ).
- the heavy chain constant region typically is comprised of three domains, CH1, CH2, and CH3.
- the hinge region is the region between the CH1 and CH2 domains of the heavy chain and is highly flexible. Disulfide bonds in the hinge region are part of the interactions between two heavy chains in an IgG molecule.
- Each light chain typically is comprised of a light chain variable region (abbreviated herein as VL or V L ) and a light chain constant region (abbreviated herein as CL or C L ).
- the light chain constant region typically is comprised of one domain, CL.
- the VH and VL regions may be further subdivided into regions of hypervariability (or hypervariable regions which may be hypervariable in sequence and/or form of structurally defined loops), also termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FRs).
- CDRs complementarity determining regions
- FRs framework regions
- Each VH and VL is typically composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 (see also Chothia and Lesk J Mol Biol 1987; 196:90117).
- CDR sequences herein are identified according to IMGT rules (Brochet X., Nucl Acids Res 2008; 36:W503-508; Lefranc M P., Nucl Acids Res 1999; 27:209-12; www.imgt.org/).
- reference to amino acid positions in the constant regions is according to the EU-numbering (Edelman et al., PNAS. 1969; 63:78-85; Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition. 1991 NIH Publication No. 91-3242).
- SEQ ID NO: 15 sets forth amino acids positions 118-447, according to EU numbering, of the IgG1 heavy chain constant region.
- amino acid corresponding to position . . . refers to an amino acid position number in a human IgG1 heavy chain. Corresponding amino acid positions in other immunoglobulins may be found by alignment with human IgG1.
- an amino acid or segment in one sequence that “corresponds to” an amino acid or segment in another sequence is one that aligns with the other amino acid or segment using a standard sequence alignment program such as ALIGN, ClustalW or similar, typically at default settings and has at least 50%, at least 80%, at least 90%, or at least 95% identity to a human IgG1 heavy chain. It is within the ability of one of ordinary skill in the art to align a sequence or segment in a sequence and thereby determine the corresponding position in a sequence to an amino acid position according to the present invention.
- antibody refers to an immunoglobulin molecule which has the ability to specifically bind to an antigen under typical physiological conditions with a half-life of significant periods of time, such as at least about 30 minutes, at least about 45 minutes, at least about one hour, at least about two hours, at least about four hours, at least about 8 hours, at least about 12 hours, about 24 hours or more, about 48 hours or more, about 3, 4, 5, 6, 7 or more days, etc., or any other relevant functionally-defined period (such as a time sufficient to induce, promote, enhance, and/or modulate a physiological response associated with antibody binding to the antigen and/or time sufficient for the antibody to recruit an effector activity).
- variable regions of the heavy and light chains of the immunoglobulin molecule contain a binding domain that interacts with an antigen.
- the term antibody also encompasses polyclonal antibodies, monoclonal antibodies (mAbs), antibody-like polypeptides, chimeric antibodies and humanized antibodies An antibody as generated can possess any isotype.
- antibody fragment or “antigen-binding fragment” as used herein refers to a fragment of an immunoglobulin molecule which retains the ability to specifically bind to an antigen, and can be generated by any known technique, such as enzymatic cleavage, peptide synthesis, and recombinant techniques.
- antibody fragments include (i) a Fab′ or Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains, or a monovalent antibody as described in WO2007059782 (Genmab); (ii) F(ab′) 2 fragments, bivalent fragments comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting essentially of the VH and CH1 domains; (iv) a Fv fragment consisting essentially of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., Nature 1989; 341: 54446), which consists essentially of a VH domain and also called domain antibodies (Holt et al; Trends Biotechnol 2003; 21:484-90); (vi) camelid or nanobodies (Revets et al; Expert Opin Biol Ther 2005; 5:
- the two domains of the Fv fragment, VL and VH are coded for by separate genes, they may be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain antibodies or single chain Fv (scFv), see, e.g., Bird et al., Science 1988; 242:42326 and Huston et al., PNAS 1988; 85:587983).
- scFv single chain antibodies or single chain Fv
- antibody-binding region or “antigen-binding region” as used herein refers to the region which interacts with the antigen and comprises both the VH and the VL regions.
- antibody when used herein refers not only to monospecific antibodies, but also multispecific antibodies which comprise multiple, such as two or more, e.g., three or more, different antigen-binding regions.
- antigen-binding region unless otherwise stated or clearly contradicted by context, includes fragments of an antibody that are antigen-binding fragments, i.e., retain the ability to specifically bind to the antigen.
- the term “isotype” refers to the immunoglobulin class (for instance IgG1, IgG2, IgG3, IgG4, IgD, IgA, IgE, or IgM) that is encoded by heavy chain constant region genes.
- IgG1 immunoglobulin class
- the term is not limited to a specific isotype sequence, e.g., a particular IgG1 sequence, but is used to indicate that the antibody is closer in sequence to that isotype, e.g. IgG1, than to other isotypes.
- an IgG1 antibody may be a sequence variant of a naturally-occurring IgG1 antibody, which may include variations in the constant regions.
- bispecific antibody or “bs” or “bsAb” as used herein refers to an antibody having two different antigen-binding regions defined by different antibody sequences.
- a bispecific antibody can be of any format.
- Fab-arm half molecule
- arm refers to one heavy chain-light chain pair.
- bispecific antibody When a bispecific antibody is described as comprising a half-molecule antibody “derived from” a first parental antibody, and a half-molecule antibody “derived from” a second parental antibody, the term “derived from” indicates that the bispecific antibody was generated by recombining, by any known method, said half-molecules from each of said first and second parental antibodies into the resulting bispecific antibody.
- recombining is not intended to be limited by any particular method of recombining and thus includes all of the methods for producing bispecific antibodies described herein, including for example recombining by half-molecule exchange (also known as “controlled Fab-arm exchange”), as well as recombining at nucleic acid level and/or through co-expression of two half-molecules in the same cells.
- full-length indicates that the antibody is not a fragment but contains all of the domains of the particular isotype normally found for that isotype in nature, e.g., the VH, CH1, CH2, CH3, hinge, VL and CL domains for an IgG1 antibody.
- a full-length antibody may be engineered.
- An example of a “full-length” antibody is epcoritamab.
- Fc region refers to an antibody region consisting of the Fc sequences of the two heavy chains of an immunoglobulin, wherein said Fc sequences comprise at least a hinge region, a CH2 domain, and a CH3 domain.
- heterodimeric interaction between the first and second CH3 regions refers to the interaction between the first CH3 region and the second CH3 region in a first-CH3/second-CH3 heterodimeric protein.
- homodimeric interactions of the first and second CH3 regions refers to the interaction between a first CH3 region and another first CH3 region in a first-CH3/first-CH3 homodimeric protein and the interaction between a second CH3 region and another second CH3 region in a second-CH3/second-CH3 homodimeric protein.
- isolated antibody refers to an antibody which is substantially free of other antibodies having different antigenic specificities.
- an isolated bispecific antibody that specifically binds to CD20 and CD3 is in addition substantially free of monospecific antibodies that specifically bind to CD20 or CD3.
- CD3 refers to the human Cluster of Differentiation 3 protein which is part of the T-cell co-receptor protein complex and is composed of four distinct chains. CD3 is also found in other species, and thus, the term “CD3” is not limited to human CD3 unless contradicted by context.
- the complex contains a CD3 ⁇ (gamma) chain (human CD3 ⁇ chain UniProtKB/Swiss-Prot No P09693, or cynomolgus monkey CD3 ⁇ UniProtKB/Swiss-Prot No Q95LI7), a CD36 (delta) chain (human CD36 UniProtKB/Swiss-Prot No P04234, or cynomolgus monkey CD36 UniProtKB/Swiss-Prot No Q95LI8), two CD3 ⁇ (epsilon) chains (human CD3 ⁇ UniProtKB/Swiss-Prot No P07766, SEQ ID NO: 28); cynomolgus CD3 ⁇ UniProtKB/Swiss-Prot No Q95LI5; or rhesus CD3 ⁇ UniProtKB/Swiss-Prot No G7NCB9), and a CD3 ⁇ -chain (zeta) chain (human CD3 ⁇ UniProtKB/Swiss
- CD3 antibody or “anti-CD3 antibody” as used herein refers to an antibody which binds specifically to the antigen CD3, in particular human CD3 ⁇ (epsilon).
- human CD20 refers to human CD20 (UniProtKB/Swiss-Prot No P11836, SEQ ID NO: 29) and includes any variants, isoforms, and species homologs of CD20 which are naturally expressed by cells, including tumor cells, or are expressed on cells transfected with the CD20 gene or cDNA.
- Species homologs include rhesus monkey CD20 ( Macaca mulatta ; UniProtKB/Swiss-Prot No H9YXP1) and cynomolgus monkey CD20 ( Macaca fascicularis ; UniProtKB No G7PQ03).
- CD20 antibody or “anti-CD20 antibody” as used herein refers to an antibody which binds specifically to the antigen CD20, in particular to human CD20.
- CD3xCD20 antibody refers to a bispecific antibody which comprises two different antigen-binding regions, one of which binds specifically to the antigen CD20 and one of which binds specifically to CD3.
- DuoBody-CD3xCD20 refers to an IgG1 bispecific CD3xCD20 antibody comprising a first heavy and light chain pair as defined in SEQ ID NO: 24 and SEQ ID NO: 25, respectively, and comprising a second heavy and light chain pair as defined in SEQ ID NO: 26 and SEQ ID NO: 27.
- the first heavy and light chain pair comprises a region which binds to human CD3 ⁇ (epsilon)
- the second heavy and light chain pair comprises a region which binds to human CD20.
- the first binding region comprises the VH and VL sequences as defined by SEQ ID NOs: 6 and 7
- the second binding region comprises the VH and VL sequences as defined by SEQ ID NOs: 13 and 14.
- This bispecific antibody can be prepared as described in WO 2016/110576.
- Antibodies comprising functional variants of the heavy chain, light chains, VL regions, VH regions, or one or more CDRs of the antibodies of the examples as also provided herein.
- a functional variant of a heavy chain, a light chain, VL, VH, or CDRs used in the context of an antibody still allows the antibody to retain at least a substantial proportion (at least about 90%, 95% or more) of functional features of the “reference” and/or “parent” antibody, including affinity and/or the specificity/selectivity for particular epitopes of CD20 and/or CD3, Fc inertness and PK parameters such as half-life, Tmax, Cmax.
- Such functional variants typically retain significant sequence identity to the parent antibody and/or have substantially similar length of heavy and light chains.
- the percent identity between two nucleotide or amino acid sequences may e.g. be determined using the algorithm of E. Meyers and W. Miller, Comput. Appl. Biosci 4, 11-17 (1988) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.
- the percent identity between two amino acid sequences may be determined using the Needleman and Wunsch, J Mol Biol 1970; 48:444-453 algorithm.
- Exemplary variants include those which differ from heavy and/or light chains, VH and/or VL, and/or CDR regions of the parent antibody sequences mainly by conservative substitutions; e.g., 10, such as 9, 8, 7, 6, 5, 4, 3, 2 or 1 of the substitutions in the variant may be conservative amino acid residue replacements.
- substitution of an amino acid in a given position is written as, e.g., K409R which means a substitution of a Lysine in position 409 with an Arginine; and ii) for specific variants the specific three or one letter codes are used, including the codes Xaa and X to indicate any amino acid residue.
- substitution of Lysine with Arginine in position 409 is designated as: K409R
- substitution of Lysine with any amino acid residue in position 409 is designated as K409X.
- deletion of Lysine in position 409 it is indicated by K409*.
- humanized antibody refers to a genetically engineered non-human antibody, which contains human antibody constant domains and non-human variable domains modified to contain a high level of sequence homology to human variable domains. This can be achieved by grafting of the six non-human antibody CDRs, which together form the antigen binding site, onto a homologous human acceptor framework region (FR) (see WO92/22653 and EP0629240). In order to fully reconstitute the binding affinity and specificity of the parental antibody, the substitution of framework residues from the parental antibody (i.e., the non-human antibody) into the human framework regions (back-mutations) may be required.
- FR human acceptor framework region
- a humanized antibody may comprise non-human CDR sequences, primarily human framework regions optionally comprising one or more amino acid back-mutations to the non-human amino acid sequence, and fully human constant regions.
- the VH and VL of the CD3 arm that is used herein in DuoBody-CD3xCD20 represents a humanized antigen-binding region.
- additional amino acid modifications which are not necessarily back-mutations, may be applied to obtain a humanized antibody with preferred characteristics, such as affinity and biochemical properties.
- human antibody refers to antibodies having variable and constant regions derived from human germline immunoglobulin sequences. Human antibodies may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). However, the term “human antibody”, as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.
- the VH and VL of the CD20 arm that is used in DuoBody-CD3xCD20 represents a human antigen-binding region.
- Human monoclonal antibodies of the invention can be produced by a variety of techniques, including conventional monoclonal antibody methodology, e.g., the standard somatic cell hybridization technique of Kohler and Milstein, Nature 256: 495 (1975). Although somatic cell hybridization procedures are preferred, in principle, other techniques for producing monoclonal antibody can be employed, e.g., viral or oncogenic transformation of B-lymphocytes or phage display techniques using libraries of human antibody genes. A suitable animal system for preparing hybridomas that secrete human monoclonal antibodies is the murine system. Hybridoma production in the mouse is a very well-established procedure. Immunization protocols and techniques for isolation of immunized splenocytes for fusion are known in the art.
- Fusion partners e.g., murine myeloma cells
- Human monoclonal antibodies can thus be generated using, e.g., transgenic or transchromosomal mice or rats carrying parts of the human immune system rather than the mouse or rat system.
- a human antibody is obtained from a transgenic animal, such as a mouse or a rat, carrying human germline immunoglobulin sequences instead of animal immunoglobulin sequences.
- the antibody originates from human germline immunoglobulin sequences introduced in the animal, but the final antibody sequence is the result of said human germline immunoglobulin sequences being further modified by somatic hypermutations and affinity maturation by the endogenous animal antibody machinery (see, e.g., Mendez et al. Nat Genet 1997; 15:146-56).
- the VH and VL regions of the CD20 arm that is used in DuoBody-CD3xCD20 represents a human antigen-binding region.
- biosimilar refers to a biologic product that is similar to the reference product based on data from (a) analytical studies demonstrating that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; (b) animal studies (including the assessment of toxicity); and/or (c) a clinical study or studies (including the assessment of immunogenicity and pharmacokinetics or pharmacodynamics) that are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is approved and intended to be used and for which approval is sought (e.g., that there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity, and potency of the product).
- the biosimilar biological product and reference product utilizes the same mechanism or mechanisms of action for the condition or conditions of use prescribed, recommended, or suggested in the proposed labeling, but only to the extent the mechanism or mechanisms of action are known for the reference product.
- the condition or conditions of use prescribed, recommended, or suggested in the labeling proposed for the biological product have been previously approved for the reference product.
- the route of administration, the dosage form, and/or the strength of the biological product are the same as those of the reference product.
- a biosimilar can be, e.g., a presently known antibody having the same primary amino acid sequence as a marketed antibody, but may be made in different cell types or by different production, purification, or formulation methods.
- reducing conditions or “reducing environment” as used herein refers to a condition or an environment in which a substrate, here a cysteine residue in the hinge region of an antibody, is more likely to become reduced than oxidized.
- Recombinant host cell (or simply “host cell”) as used herein is intended to refer to a cell into which an expression vector has been introduced, e.g., an expression vector encoding an antibody described herein.
- Recombinant host cells include, for example, transfectomas, such as CHO, CHO-S, HEK, HEK293, HEK-293F, Expi293F, PER.C6 or NS0 cells, and lymphocytic cells.
- DLBCL diffuse large B-cell lymphoma
- DLBCL diffuse large B-cell lymphoma
- DLBCL Double hit and “triple hit” DLBCL refers to DLBCL with MYC and BCL2 and/or BCL6 translocations, falling under the category of high-grade B cell lymphoma (HGBCL) with MYC and BCL2 and/or BCL6 translocations, in accordance with the WHO 2016 classification (Swerdlow S H, Campo E, Harris N L, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised ed. 4th). Lyon, France: IARC Press (2017), the contents of which are herein incorporated by reference). Follicular lymphoma grade 3B is also often considered to be equivalent to DLBCL and thus treated as such.
- HGBCL high-grade B cell lymphoma
- R-CHOP refers to a drug combination containing rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.
- the term “R-CHOP” is also intended to encompass regimens in which the rituximab component is replaced with a biosimilar thereof, and/or branded or generic versions (generic equivalents) of cyclophosphamide, doxorubicin, vincristine, and/or prednisone, as well as pharmaceutically acceptable salts, isomers, racemates, solvates, complexes and hydrates, anhydrate forms thereof, and any polymorphic or amorphous forms thereof or combinations thereof, are used in the methods described herein.
- rituximab refers to a genetically engineered chimeric human gamma 1 murine constant domain containing monoclonal antibody against human CD20.
- the chimeric antibody contains human gamma 1 constant domains and is referred to as “C2B8” in U.S. Pat. No. 5,736,137 (the entire content of which is herein incorporated by reference).
- Rituximab is commercially available, for example, as Rituxan®, MabThera®, or Zytux®.
- rituximab can be replaced with a biosimilar thereof. Accordingly, it will be understood that the term “rituximab” is intended to encompass biosimilars of rituximab. Also encompassed by the term “rituximab” are antibodies which have CDRs, variable regions, or heavy and light chains of rituximab. Non-limiting examples of biosimilars of rituximab include Truxima® (rituximab-abbs), Ruxience® (rituximab-pvvr), and Rixathon®. The biosimilar may be administered according to a standard of care dosage, or at a dose equivalent to the standard of care dosage specified for rituximab.
- cyclophosphamide refers to a nitrogen mustard alkylating agent with the chemical name 2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (CAS No. 50-18-0) and has the chemical formula C 7 H 15 Cl 2 N 2 O 2 P. It is marketed under trade names such as Endoxan®, Cytoxan®, Neosar®, Procytox®, and Revimmune®.
- cyclophosphamide is also intended to encompass branded and generic versions (generic equivalents) of cyclophosphamide, as well as pharmaceutically acceptable salts, isomers, racemates, solvates, complexes and hydrates, anhydrate forms thereof, and any polymorphic or amorphous forms thereof or combinations thereof.
- doxorubicin refers to an anthracycline antibiotic, closely related to the natural product daunomycin, and like all anthracyclines, it works by intercalating DNA.
- Doxorubicin is marketed under trade names such as Adriamycin PFS®, Adriamycin RDF®, or Rubex®.
- the drug is administered intravenously, in the form of hydrochloride salt (e.g., as doxorubicin hydrochloride).
- Doxorubicin hydrochloride has the chemical name 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy- ⁇ -L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S,10S)-(CAS No. 25316-40-9), and has the chemical formula C 27 H 29 NO 11 ⁇ HCl.
- doxorubicin is also intended to encompass branded and generic versions (generic equivalents) of doxorubicin, as well as pharmaceutically acceptable salts, isomers, racemates, solvates, complexes and hydrates, anhydrate forms thereof, and any polymorphic or amorphous forms thereof or combinations thereof.
- vincristine also known as leurocristine
- vinca alkaloid chemotherapy agent used to treat various types of cancer. It is marketed under trade names such as Oncovin® and Vincasar PFS®. Liposomally formulated vincristine sulfate is marketed under the trade name Marquibo®.
- vincristine is also intended to encompass branded and generic versions (generic equivalents) of vincristine, as well as pharmaceutically acceptable salts, isomers, racemates, solvates, complexes and hydrates, anhydrate forms thereof, and any polymorphic or amorphous forms thereof or combinations thereof.
- Prednisone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties. It is a prodrug that is metabolized in the liver to prednisolone, the active form of the drug. Prednisone is marketed under trade names such as Deltasone®, Liquid Pred®, Rayos®, and Orasone®, among others. Prednisone has the chemical name 17,21-dihydroxypregna-1,4-diene-3,11,20-trione (CAS No. 53-03-2).
- prednisone is also intended to encompass branded and generic versions (generic equivalents) of prednisone, as well as pharmaceutically acceptable salts, isomers, racemates, solvates, complexes and hydrates, anhydrate forms thereof, and any polymorphic or amorphous forms thereof or combinations thereof.
- treatment refers to the administration of an effective amount of a therapeutically active antibody described herein for the purpose of easing, ameliorating, arresting or eradicating (curing) symptoms or disease states such as DLBCL.
- Treatment may result in a complete response (CR), partial response (PR), or stable disease (SD), for example, as defined by Lugano criteria and/or LYRIC.
- Treatment may be continued, for example, for up to one year total duration of treatment with the bispecific antibody from initiation of R-CHOP, or up to disease progression or unacceptable toxicity.
- administering refers to the physical introduction of a composition (or formulation) comprising a therapeutic agent to a subject, using any of the various methods and delivery systems known to those skilled in the art.
- Preferred routes of administration for antibodies described herein include intravenous, intraperitoneal, intramuscular, subcutaneous, spinal or other parenteral routes of administration, for example by injection or infusion.
- parenteral administration means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intraperitoneal, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion, as well as in vivo electroporation.
- a therapeutic agent described herein can be administered via a non-parenteral route, such as a topical, epidermal or mucosal route of administration, for example, intranasally, orally, vaginally, rectally, sublingually or topically.
- Administering can also be performed, for example, once, a plurality of times, and/or over one or more extended periods.
- the bispecific antibody e.g., epcoritamab
- agents used in combination with the bispecific antibody such as for R-CHOP, cytokine release syndrome prophylaxis, and/or tumor lysis syndrome (TLS) prophylaxis, may be administered via other routes, such as intravenously or orally.
- TLS tumor lysis syndrome
- an effective amount or “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result.
- dosages as defined herein for the bispecific antibody e.g., epcoritamab
- 24 mg or 48 mg administered subcutaneously can be defined as such an “effective amount” or “therapeutically effective amount”.
- a therapeutically effective amount of an antibody may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the antibody to elicit a desired response in the individual.
- a therapeutically effective amount is also one in which any toxic or detrimental effects of the antibody or antibody portion are outweighed by the therapeutically beneficial effects.
- a therapeutically effective amount or dosage of a drug includes a “prophylactically effective amount” or a “prophylactically effective dosage”, which is any amount of the drug that, when administered alone or in combination with another therapeutic agent to a subject at risk of developing a disease or disorder (e.g., cytokine release syndrome) or of suffering a recurrence of disease, inhibits the development or recurrence of the disease.
- a disease or disorder e.g., cytokine release syndrome
- the term “inhibits growth” of a tumor as used herein includes any measurable decrease in the growth of a tumor, e.g., the inhibition of growth of a tumor by at least about 10%, for example, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 99%, or 100%.
- subject refers to a human patient, for example, a human patient with DLBCL.
- subject and patient are used interchangeably herein.
- buffer as used herein denotes a pharmaceutically acceptable buffer.
- the term “buffer” encompasses those agents which maintain the pH value of a solution, e.g., in an acceptable range and includes, but is not limited to, acetate, histidine, TRIS® (tris (hydroxymethyl) aminomethane), citrate, succinate, glycolate and the like.
- the “buffer” as used herein has a pKa and buffering capacity suitable for the pH range of about 5 to about 6, preferably of about 5.5.
- Disease progression refers to a situation in which one or more indices of DLBCL show that the disease is advancing despite treatment.
- disease progression is defined based on the Lugano Response Criteria for Malignant Lymphoma (“Lugano criteria”) and/or Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC). Details regarding the Lugano criteria/classification system, including definitions for complete response (CR), partial response (PR), no response/stable disease (NR/SD), and progressive disease (PD) are provided in Cheson et al. J Clin Oncol 2014; 32:3059-68, the contents of which are incorporated by reference herein (see, in particular, Table 3 in Cheson et al., 2014). Details regarding LYRIC are provided in Table 11.
- a “surfactant” as used herein is a compound that is typically used in pharmaceutical formulations to prevent drug adsorption to surfaces and or aggregation. Furthermore, surfactants lower the surface tension (or interfacial tension) between two liquids or between a liquid and a solid. For example, an exemplary surfactant can significantly lower the surface tension when present at very low concentrations (e.g., 5% w/v or less, such as 3% w/v or less, such as 1% w/v or less such as 0.4% w/v or less, such as below 0.1% w/v or less, such as 0.04% w/v).
- very low concentrations e.g., 5% w/v or less, such as 3% w/v or less, such as 1% w/v or less such as 0.4% w/v or less, such as below 0.1% w/v or less, such as 0.04% w/v).
- Surfactants are amphiphilic, which means they are usually composed of both hydrophilic and hydrophobic or lipophilic groups, thus being capable of forming micelles or similar self-assembled structures in aqueous solutions.
- Known surfactants for pharmaceutical use include glycerol monooleate, benzethonium chloride, sodium docusate, phospholipids, polyethylene alkyl ethers, sodium lauryl sulfate and tricaprylin (anionic surfactants); benzalkonium chloride, citrimide, cetylpyridinium chloride and phospholipids (cationic surfactants); and alpha tocopherol, glycerol monooleate, myristyl alcohol, phospholipids, poloxamers, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbintan fatty acid esters, polyoxyethylene sterarates, polyoxyl hydroxystearate, polyoxylglycerides, polysorbates such
- a “diluent” as used herein is one which is pharmaceutically acceptable (safe and non-toxic for administration to a human) and is useful for the preparation of dilutions of the pharmaceutical composition or pharmaceutical formulation (the terms “composition” and “formulation” are used interchangeably herein).
- dilutions of the composition dilute only the antibody concentration but not the buffer and stabilizer.
- the diluent contains the same concentrations of the buffer and stabilizer as is present in the pharmaceutical composition of the invention.
- exemplary diluents include sterile water, bacteriostatic water for injection (BWFI), a pH buffered solution which is preferably an acetate buffer, sterile saline solution such as water for injection, Ringer's solution or dextrose solution.
- BWFI bacteriostatic water for injection
- a pH buffered solution which is preferably an acetate buffer
- sterile saline solution such as water for injection
- Ringer's solution or dextrose solution sterile saline solution
- the diluent comprises or consists essentially of acetate buffer and sorbitol.
- the term “about” refers to a value that is no more than 10% above and no more than 10% below a specified value.
- anti-CD3xCD20 antibody an isolated anti-CD3xCD20 antibody such as epcoritamab which binds to human CD3 and human CD20
- R-CHOP i.e., rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
- the methods are useful for treating, e.g., previously untreated, high-risk (IPI or R-IPI ⁇ 3) DLBCL.
- DLBCL e.g., newly-diagnosed, previously untreated, high-risk (IPI or R-IPI 3-5) DLBCL
- methods of treating DLBCL with a bispecific antibody which binds to both CD3 and CD20 described herein also encompass corresponding uses of the bispecific antibody for treating DLBCL (e.g., newly-diagnosed, previously untreated, high-risk (IPI or R-IPI 3-5) DLBCL) in a human subject.
- a method of treating DLBCL in a human subject comprising administering a bispecific antibody and an effective amount of (a) rituximab, (b) cyclophosphamide, (c) doxorubicin, (d) vincristine, and (e) prednisone, wherein the bispecific antibody comprises:
- the bispecific antibody is a full-length antibody. In some embodiments, the bispecific antibody is an antibody with an inert Fc region. In some embodiments, the bispecific antibody is a full-length antibody with an inert Fc region.
- the bispecific antibody is administered at a dose of (or a dose of about) 24 mg. In some embodiments, the bispecific antibody is administered at a dose of (or a dose of about) 48 mg.
- the dose of (or dose of about) 24 mg or 48 mg of the bispecific antibody that is to be administered, or any other specified dose refers to the amount of a bispecific antibody representing a full-length antibody, such as epcoritamab as defined in the Examples section.
- administering a dose of a bispecific antibody of 24 mg as administering a dose of a bispecific antibody described herein, wherein the dose corresponds to a dose of 24 mg of epcoritamab.
- the amount of antibody to be administered when, for example, the antibody used differs substantially in molecular weight from the molecular weight of a full-length antibody such as epcoritamab.
- the amount of antibody can be calculated by dividing the molecular weight of the antibody by the weight of a full-length antibody such as epcoritamab and multiplying the outcome thereof with the specified dose as described herein.
- the bispecific antibody e.g., a functional variant of DuoBody CD3xCD20
- the bispecific antibody has highly similar features as DuoBody CD3xCD20, with regard to plasma half-life, Fc inertness, and/or binding characteristics for CD3 and CD20, i.e., with regard to CDRs and epitope binding features, such antibodies are suitable for use in the methods provided herein at a dose described for a full-length antibody such as epcoritamab.
- the dose of bispecific antibody is administered once every week (weekly administration) in 21-day cycles.
- the weekly dose of 24 mg or 48 mg is administered for three and one-third 21-day cycles (i.e., 10 times; on day 15 of cycle 1, and days 1, 8, and 15 of cycles 2-4).
- the weekly dose of 24 mg is administered for three and one-third 21-day cycles (i.e., 10 times; on day 15 of cycle 1, and days 1, 8, and 15 of cycles 2-4).
- the weekly dose of 48 mg is administered for three and one-third 21-day cycles (i.e., 10 times; on day 15 of cycle 1, and days 1, 8, and 15 of cycles 2-4).
- the administration once every three weeks is performed for two or four 21-day cycles (i.e., two or four times, respectively). In one embodiment, the administration once every three weeks is performed for two 21-day cycles (i.e., two times). In one embodiment, the administration once every three weeks is performed for four 21-day cycles (i.e., two times). In some embodiments, after the administration once every three weeks in 21-day cycles, one may reduce the interval of administration to once every four weeks in 28-day cycles i.e. after the administration once every three weeks, the bispecific antibody is administered once every four weeks in 28-day cycles.
- the administration once every four weeks in 28-day cycles is performed for up to one year total duration of treatment with the bispecific antibody.
- the administration once every four weeks in 28-day cycles may be performed for an extended period, for example, for at least 1 cycle, at least 2 cycles, at least 3 cycles, at least 4 cycles, at least 5 cycles, at least 6 cycles, at least 7 cycles, at least 8 cycles, at least 9 cycles, at least 10 cycles, at least 11 cycles, at least 12 cycles, at least 13 cycles, at least 14 cycles, at least 15 cycles, or between 1-20 cycles, 1-19 cycles, 1-18 cycles, 1-17 cycles, 1-16 cycles, 1-15 cycles, 1-14 cycles, 1-13 cycles, 1-12 cycles, 1-10 cycles, 1-5 cycles, 5-20 cycles, 5-15 cycles, 5-10 cycles 10-20 cycles, 10-15 cycles, or 15-20 cycles.
- the bispecific antibody is administered once every four weeks from cycle 7 or cycle 9 (i.e., cycle starting after the bispecific antibody+R-CHOP combination has ended) to cycle 17 of the 28-day cycles. In some embodiments, the bispecific antibody is administered once every four weeks from cycle 7 or cycle 9 for up to one year total duration of treatment with the bispecific antibody from initiation of R-CHOP. In a further embodiment, the bispecific antibody is administered from cycle 7 or cycle 9 of the 28-day cycles until disease progression (e.g., as defined by the Lugano criteria or LYRIC) or unacceptable toxicity.
- disease progression e.g., as defined by the Lugano criteria or LYRIC
- the weekly dose of the bispecific antibody is administered in 21-day cycles on cycles 1-4 (which may include priming and intermediate doses, as described below), the dose once every three weeks of the bispecific antibody is administered in 21-day cycles on cycles 5-6 or 5-8, and the dose once every four weeks is administered in 28-day cycles from cycle 7 or 9 onwards, for example, on cycles 7-17 or 9-17, or more cycles, e.g., for up to one year total duration of treatment with the bispecific antibody from initiation of R-CHOP, or until disease progression or unacceptable toxicity is observed in the subject.
- the dose once every four weeks in 28-day cycles is administered on cycles 7-17 or 9-17.
- the doses referred to herein may also be referred to as a full or a flat dose in the scenarios above wherein, e.g., the weekly dose, dose once every three weeks, and/or the dose every four weeks is administered at the same level. Accordingly, when a dose of 48 mg is selected, preferably, at each weekly administration, at each administration once every three weeks, and each administration every four weeks, the same dose of 48 mg is administered.
- a priming or a priming and subsequent intermediate (second priming) dose may be administered prior to administering the dose. This may be advantageous as it may help mitigate cytokine release syndrome (CRS) risk and severity, a side-effect that can occur during treatment with the bispecific anti-CD3xCD20 antibody described herein.
- Such priming, or priming and intermediate doses are at a lower dose as compared with the flat or full dose.
- a priming dose of the bispecific antibody may be administered prior to administering the weekly dose of 24 mg or 48 mg.
- the priming dose is administered two weeks prior to administering the first weekly dose of 24 mg or 48 mg in cycle 1.
- the priming dose is 0.16 mg (or about 0.16 mg) of the full-length bispecific antibody.
- the priming dose of 0.16 mg is administered two weeks prior to administering the first weekly dose of 24 mg in cycle 1.
- the priming dose of 0.16 mg is administered two weeks prior to administering the first weekly dose of 48 mg in cycle 1.
- an intermediate dose of said bispecific antibody is administered.
- the priming dose is administered one week before the intermediate dose (i.e., on day 1 of cycle 1), and the intermediate dose is administered one week before the first weekly dose of 24 mg or 48 mg (i.e., on day 8 of cycle 1).
- the priming dose is administered on day 1 and the intermediate dose is administered on day 8 before the first weekly dose of 24 mg or 48 mg on day 15 of cycle.
- the intermediate dose is 800 ⁇ g (0.8 mg) or about 800 ⁇ g (0.8 mg) of the full-length bispecific antibody.
- the priming dose of 0.16 mg is administered one week before the intermediate dose (i.e., on day 1 of cycle 1) of 0.8 mg, and the intermediate dose is administered one week before the first weekly dose of 24 mg (i.e., on day 8 of cycle 1). In one embodiment, the priming dose of 0.16 mg is administered one week before the intermediate dose (i.e., on day 1 of cycle 1) of 0.8 mg, and the intermediate dose is administered one week before the first weekly dose of 48 mg (i.e., on day 8 of cycle 1).
- the methods described herein involve treating human subjects who have DLBCL with a bispecific antibody which binds to CD3 and CD20 in combination with a standard-of-care regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.
- rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone are administered at standard-of-care dosages for R-CHOP, e.g., as supported by clinical studies, according to local guidelines, and/or according to relevant local labels.
- rituximab is administered according to relevant local product labels or summary of product characteristics (see, e.g., RITUXAN® (rituximab) prescribing information, available at www.accessdata.fda.gov/drugsatfda_docs/label/2013/103705s54141b1.pdf).
- a biosimilar of rituximab is used in place of rituximab in the methods described herein.
- cyclophosphamide is administered according to relevant local product labels or summary of product characteristics (see, e.g., CYCLOPHOSPHAMIDE injection prescribing information, available at www.accessdata.fda.gov/drugsatfda_docs/label/2013/012141s090,012142s1121b1.pdf).
- doxorubicin is administered according to relevant local product labels or summary of product characteristics (see, e.g., ADRIAMYCIN (DOXOrubicin HCl) for Injection (lyophilized) and ADRIAMYCIN (DOXOrubicin HCL) Injection (0.9% sodium chloride and water) prescribing information, available at www.accessdata.fda.gov/drugsatfda_docs/label/2012/062921s0221b1.pdf, Doxorubicin Hydrochloride for Injection and Doxorubicin Hydrochloride Injection prescribing information available at www.accessdata.fda.gov/drugsatfda_docs/label/2010/050467s0701b1.pdf).
- vincristine is administered according to relevant local product labels or summary of product characteristics (see, e.g., VinCRIStine Sulfate Injection prescribing information, available at www.accessdata.fda.gov/drugsatfda_docs/label/2014/071484s0421b1.pdf).
- prednisolone is administered in place of prednisone in the R-CHOP regimen.
- rituximab is administered according to local guidelines and local labels. In some embodiments, rituximab is administered at a dose of (or a dose of about) 375 mg/m 2 . In some embodiments, rituximab is administered intravenously.
- rituximab is administered once every three weeks. In some embodiments, rituximab is administered once every three weeks (Q3 W) in 21-day cycles. In some embodiments, administration of rituximab once every three weeks is performed for six or eight 21-day cycles (i.e., six or eight times, respectively). In preferred embodiments, rituximab is administered intravenously once every three weeks for six 21-day cycles (i.e., six times) at a dose of 375 mg/m 2 . In preferred embodiments, rituximab is administered intravenously once every three weeks for eight 21-day cycles (i.e., eight times) at a dose of 375 mg/m 2 .
- cyclophosphamide is administered according to local guidelines and local labels. In some embodiments, cyclophosphamide is administered at a dose of (or a dose of about) 750 mg/m 2 . In some embodiments, cyclophosphamide is administered intravenously. In some embodiments, cyclophosphamide is administered once every three weeks. In some embodiments, rituximab is administered once every three weeks (Q3 W) in 21-day cycles. In some embodiment, administration of cyclophosphamide once every three weeks is performed for six or eight 21-day cycles (i.e., six or eight times, respectively).
- cyclophosphamide is administered intravenously once every three weeks for six 21-day cycles (i.e., six times) at a dose of 750 mg/m 2 .
- cyclophosphamide is administered intravenously once every three weeks for eight 21-day cycles (i.e., eight times) at a dose of 750 mg/m 2 .
- doxorubicin is administered according to local guidelines and local labels. In some embodiments, doxorubicin is administered at a dose of (or a dose of about) 50 mg/m 2 . In some embodiments, doxorubicin is administered intravenously. In some embodiments, doxorubicin is administered once every three weeks. In some embodiments, doxorubicin is administered once every three weeks (Q3 W) in 21-day cycles. In some embodiments, administration of doxorubicin once every three weeks is performed for six or eight 21-day cycles (i.e., six or eight times, respectively).
- doxorubicin is administered intravenously once every three weeks for six 21-day cycles (i.e., six times) at a dose of 50 mg/m 2 .
- doxorubicin is administered intravenously once every three weeks for eight 21-day cycles (i.e., eight times) at a dose of 50 mg/m 2 .
- vincristine is administered according to local guidelines and local labels. In some embodiments, vincristine is administered at a dose of (or a dose of about) 1.4 mg/m 2 . In some embodiments, the maximum dose of vincristine administered to the subject is below 2 mg. In a further embodiment, vincristine is administered intravenously. In some embodiments, vincristine is administered once every three weeks. In some embodiments, vincristine is administered once every three weeks (Q3 W) in 21-day cycles. In some embodiments, administration of vincristine once every three weeks is performed for six or eight 21-day cycles (i.e., six or eight times).
- vincristine is administered intravenously once every three weeks for six 21-day cycles (i.e., six times) at a dose of less than 2 mg/m 2 .
- vincristine is administered intravenously once every three weeks for eight 21-day cycles (i.e., eight times) at a dose of less than 2 mg/m 2 .
- vincristine is administered intravenously once every three weeks for six 21-day cycles (i.e., six times) at a dose of 1.4 mg/m 2 .
- vincristine is administered intravenously once every three weeks for eight 21-day cycles (i.e., eight times) at a dose of 1.4 mg/m 2 .
- rituximab is preferably administered at a dose of 375 mg/m 2
- cyclophosphamide is preferably administered at a dose of 750 mg/m 2
- doxorubicin is preferably administered at a dose of 50 mg/m 2
- vincristine is preferably administered at a dose of 1.4 mg/m 2
- rituximab, cyclophosphamide, doxorubicin and vincristine is preferably administered intravenously once every three weeks for six 21-day cycles.
- prednisone is administered according to local guidelines and local labels. In some embodiments, prednisone is administered at a dose of (or a dose of about) 100 mg. In some embodiment, prednisone is administered intravenously and/or orally. In some embodiments, prednisone is administered intravenously. In some embodiments, prednisone is administered orally.
- prednisone is administered once a day for five consecutive days (i.e., days 1-5) in 21-day cycles. In one embodiment, prednisone is administered for six or eight 21-day cycles (e.g., on days 1-5 of cycles 1-6 or cycles 1-8 of the 21-day cycles). In one embodiment, prednisone is administered once a day on days 1-5 in 21-day cycles. In some embodiments, prednisone is administered once a day for five consecutive days (i.e., days 1-5) for six or eight 21-day cycles (e.g., on days 1-5 of cycles 1-6 or cycles 1-8 of the 21-day cycles).
- prednisone is administered intravenously once a day for five consecutive days (i.e., days 1-5) for six 21-day cycles (e.g., on days 1-5 of cycles 1-6 of the 21-day cycles) at a dose of 100 mg/day.
- prednisone is administered intravenously once a day for five consecutive days (i.e., days 1-5) for eight 21-day cycles (e.g., on days 1-5 of cycles 1-8 of the 21-day cycles) a dose of 100 mg/day.
- prednisone is administered orally once a day for five consecutive days (i.e., days 1-5) for six 21-day cycles (e.g., on days 1-5 of cycles 1-6 of the 21-day cycles) at a dose of 100 mg/day.
- prednisone is administered orally once a day for five consecutive days (i.e., days 1-5) for eight 21-day cycles (e.g., on days 1-5 of cycles 1-8 of the 21-day cycles) a dose of 100 mg/day.
- prednisone is administered intravenously and/or orally once a day for five consecutive days (i.e., days 1-5) for six 21-day cycles (e.g., on days 1-5 of cycles 1-6 of the 21-day cycles) at a dose of 100 mg/day.
- prednisone is administered intravenously and/or orally once a day for five consecutive days (i.e., days 1-5) for eight 21-day cycles (e.g., on days 1-5 of cycles 1-8 of the 21-day cycles) a dose of 100 mg/day.
- the dose of cyclophosphamide or doxorubicin is reduced when a subject presents with cyclophosphamide- or doxorubicin-related hematological toxicities during a treatment cycle in accordance with standard of care guidelines, for example, as specified in the product label. See, for example, Table 8 for dose modification criteria or cyclophosphamide and doxorubicin (see also Table 9).
- the dose of vincristine is reduced when a subject presents with impaired hepatic function, e.g., using serum bilirubin levels as a marker. For example, if a subject has serum bilirubin levels of 2-3 mg/dL, then the dose of vincristine is reduced to 75% of the normal dose. If a subject has serum bilirubin levels of >3.0 mg/dL, then the dose of vincristine is reduced to 50% of the normal dose. Vincristine can be re-escalated when hyperalbuminemia improves.
- the dose of prednisone (or equivalent) is reduced according to local prescribing information. For example, when a subject develops an adverse event related to corticosteroid and cannot tolerate the 100 mg/day dose (or equivalent), then the dose may be reduced to no less than 80 mg/day. In some embodiments, the dose reduction of prednisone (or equivalent) is performed in a tapering regimen.
- the bispecific antibody, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone are administered simultaneously.
- the bispecific antibody, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone are administered sequentially.
- the bispecific antibody, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone are administered on the same day.
- prednisone is administered first, rituximab is administered second, cyclophosphamide is administered third, doxorubicin is administered fourth, vincristine is administered fifth, and the bispecific antibody is administered last.
- the subject is administered premedication and/or prophylaxis for CRS prior to administration of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, and the bispecific antibody.
- the prednisone component of the R-CHOP regimen is used as the corticosteroid in CRS prophylaxis.
- rituximab e.g., intravenous
- cyclophosphamide e.g., intravenous
- doxorubicin e.g., intravenous
- vincristine e.g., intravenous
- prednisone e.g., intravenous or oral
- bispecific antibody e.g., subcutaneous
- rituximab e.g., intravenous
- cyclophosphamide e.g., intravenous
- doxorubicin e.g., intravenous
- vincristine e.g., intravenous
- prednisone e.g., intravenous or oral
- bispecific antibody e.g., subcutaneous
- the bispecific antibody is administered once every four weeks in 28-day cycles from cycle 7 (e.g., from cycle 7-cycle 15, from cycle 7 to cycle 17, from cycle 7 to cycle 20, or from cycle 7 up to one year total duration of treatment with the bispecific antibody from initiation of R-CHOP).
- cycle 7 e.g., from cycle 7-cycle 15, from cycle 7 to cycle 17, from cycle 7 to cycle 20, or from cycle 7 up to one year total duration of treatment with the bispecific antibody from initiation of R-CHOP.
- rituximab is preferably administered at a dose of 375 mg/m 2
- cyclophosphamide is preferably administered at a dose of 750 mg/m 2
- doxorubicin is preferably administered at a dose of 50 mg/m 2
- vincristine is preferably administered at a dose of 1.4 mg/m 2
- prednisone is preferably administered at a dose of 100 mg/day.
- rituximab e.g., intravenous
- cyclophosphamide e.g., intravenous
- doxorubicin e.g., intravenous
- vincristine e.g., intravenous
- prednisone e.g., intravenous or oral
- bispecific antibody e.g., subcutaneous
- rituximab e.g., intravenous
- cyclophosphamide e.g., intravenous
- doxorubicin e.g., intravenous
- vincristine e.g., intravenous
- prednisone e.g., intravenous or oral
- bispecific antibody e.g., subcutaneous
- the bispecific antibody is administered once every four weeks in 28-day cycles from cycle 9 (e.g., from cycle 9-cycle 15, from cycle 9 to cycle 17, from cycle 9 to cycle 20, or for up to one year total duration of treatment with the bispecific antibody from initiation of R-CHOP).
- cycle 9 e.g., from cycle 9-cycle 15, from cycle 9 to cycle 17, from cycle 9 to cycle 20, or for up to one year total duration of treatment with the bispecific antibody from initiation of R-CHOP.
- rituximab is preferably administered at a dose of 375 mg/m 2
- cyclophosphamide is preferably administered at a dose of 750 mg/m 2
- doxorubicin is preferably administered at a dose of 50 mg/m 2
- vincristine is preferably administered at a dose of 1.4 mg/m 2
- prednisone is preferably administered at a dose of 100 mg/day.
- rituximab e.g., intravenous
- cyclophosphamide e.g., intravenous
- doxorubicin e.g., intravenous
- vincristine e.g., intravenous
- prednisone e.g., intravenous or oral
- bispecific antibody epcoritamab e.g., subcutaneous
- rituximab e.g., intravenous
- cyclophosphamide e.g., intravenous
- doxorubicin e.g., intravenous
- vincristine e.g., intravenous
- prednisone e.g., intravenous or oral
- bispecific antibody epcoritamab e.g., subcutaneous
- the bispecific antibody epcoritamab is further administered once every four weeks in 28-day cycles from cycle 7 (e.g., from cycle 7-cycle 15, from cycle 7 to cycle 17, from cycle 7 to cycle 20, or from cycle 9 up to one year total duration of treatment with the bispecific antibody from initiation of R-CHOP).
- cycle 7 e.g., from cycle 7-cycle 15, from cycle 7 to cycle 17, from cycle 7 to cycle 20, or from cycle 9 up to one year total duration of treatment with the bispecific antibody from initiation of R-CHOP).
- rituximab is preferably administered at a dose of 375 mg/m 2
- cyclophosphamide is preferably administered at a dose of 750 mg/m 2
- doxorubicin is preferably administered at a dose of 50 mg/m 2
- vincristine is preferably administered at a dose of 1.4 mg/m 2
- prednisone is preferably administered at a dose of 100 mg/day.
- rituximab e.g., intravenous
- cyclophosphamide e.g., intravenous
- doxorubicin e.g., intravenous
- vincristine e.g., intravenous
- prednisone e.g., intravenous or oral
- bispecific antibody epcoritamab e.g., subcutaneous
- rituximab e.g., intravenous
- cyclophosphamide e.g., intravenous
- doxorubicin e.g., intravenous
- vincristine e.g., intravenous
- prednisone e.g., intravenous or oral
- bispecific antibody epcoritamab e.g., subcutaneous
- the bispecific antibody epcoritamab is further administered once every four weeks in 28-day cycles from cycle 9 (e.g., from cycle 9-cycle 15, from cycle 9 to cycle 17, from cycle 9 to cycle 20, or from cycle 9 up to one year total duration of treatment with the bispecific antibody from initiation of R-CHOP).
- cycle 9 e.g., from cycle 9-cycle 15, from cycle 9 to cycle 17, from cycle 9 to cycle 20, or from cycle 9 up to one year total duration of treatment with the bispecific antibody from initiation of R-CHOP).
- rituximab is preferably administered at a dose of 375 mg/m 2
- cyclophosphamide is preferably administered at a dose of 750 mg/m 2
- doxorubicin is preferably administered at a dose of 50 mg/m 2
- vincristine is preferably administered at a dose of 1.4 mg/m 2
- prednisone is preferably administered at a dose of 100 mg/day.
- subjects considered to be at risk of thrombosis are administered prophylactic antithrombotic treatment, such as low-dose aspirin (e.g., 70-100 mg daily).
- prophylactic antithrombotic treatment such as low-dose aspirin (e.g., 70-100 mg daily).
- subjects with a prior history of deep vein thrombosis (DVT) or pulmonary embolism (PE) are administered anticoagulation therapy.
- the subject undergoing the treatment with the methods described herein has documented DLBCL (de novo or histologically transformed from indolent lymphomas, except for CLL) according to the WHO 2016 classification. Accordingly, in one embodiment, the subject has DLBCL, NOS (not otherwise specified). In some embodiments, the subject has “double hit” or “triple hit” DLBCL, which are classified in WHO 2016 as HGBCL, with MYC and BCL2 and/or BCL6 translocations. In some embodiments, the subject has follicular lymphoma Grade 3B.
- the subject with DLBCL has a Revised International Prognostic Index (R-IPI) score ⁇ 3, such as an R-IPI score of 3, 4, or 5.
- IPI risk factors include (1) Ann Arbor Stage III or IV, (2) age >60 years, (3) Lactate dehydrogenase level elevated, (4) ECOG performance score ⁇ 2, and (5) more than 1 extranodal site.
- R-IPI scoring is based on the number of above risk factors (1)-(5).
- R-IPI risk groups are categorized as Very good (0 IPI risk factors), Good (1 or 2 IPI risk factors), and Poor (3-5 IPI risk factors).
- R-IPI applies to subjects with newly diagnosed DLBCL who are receiving R-CHOP as first-line therapy. See, e.g., Information regarding the R-IPI is available, e.g., in Sehn et al., Blood 2007; 109:1857-71.
- the subject with DLBCL has not received prior therapy for DLBCL or follicular lymphoma Grade 3B.
- the subject has an Eastern Cooperative Oncology Group (ECOG) performance status (ECOG PS) of 0, 1, or 2.
- ECOG PS Eastern Cooperative Oncology Group
- Information regarding ECOG PS scores can be found in, e.g., Oken et al, Am J Clin Oncol 1982 December; 5(6):649-55).
- the subject has measurable disease as defined as (a) ⁇ 1 measurable nodal lesion (long axis >1.5 cm and short axis >1.0 cm) or ⁇ 1 measurable extra-nodal lesion (long axis >1 cm) on CT or MRI.
- the subject has acceptable organ function as defined as: (a) ANC ⁇ 1.0 ⁇ 10 9 /L, (b) platelet count >75 ⁇ 10 9 /L, or ⁇ 50 ⁇ 10 9 /L if bone marrow infiltration or splenomegaly, (c) ALT level ⁇ 2.5 times the ULN, (d) total bilirubin level ⁇ 2 ⁇ ULN, (e) eGFR >50 mL/min (by Cockcroft-Gault Formula), and (f) PT, INR, and aPTT ⁇ 1.5 ⁇ ULN (unless receiving anticoagulant).
- organ function as defined as: (a) ANC ⁇ 1.0 ⁇ 10 9 /L, (b) platelet count >75 ⁇ 10 9 /L, or ⁇ 50 ⁇ 10 9 /L if bone marrow infiltration or splenomegaly, (c) ALT level ⁇ 2.5 times the ULN, (d) total bilirubin level ⁇ 2 ⁇ ULN, (e) eGFR >
- the subject does not have severe allergic or anaphylactic reactions to anti-CD20 antibody therapy, any component of CHOP (i.e., cyclophosphamide, doxorubicin, vincristine, and prednisone), or the bispecific antibody, or known allergy or intolerance to any component or excipient of rituximab, CHOP, and/or the bispecific antibody.
- any component of CHOP i.e., cyclophosphamide, doxorubicin, vincristine, and prednisone
- the bispecific antibody or known allergy or intolerance to any component or excipient of rituximab, CHOP, and/or the bispecific antibody.
- the subject has not received prior therapy for DLBCL (with the exception of nodal biopsy). In some embodiments, the subject does not have a contraindication to any individual drug in the R-CHOP regimen.
- the subject does not have clinically significant cardiac disease, including (a) myocardial infarction within one year prior to the first dose of the bispecific antibody, or unstable or uncontrolled disease/condition related to or affecting cardiac function (e.g., unstable angina, congestive heart failure, NYHA class III-IV), cardiac arrhythmia (CTCAE Version 4 Grade 2 or higher), or clinically significant ECG abnormalities, and/or (b) 12-lead ECG showing a baseline QTcF >470 msec.
- cardiac function e.g., unstable angina, congestive heart failure, NYHA class III-IV
- CCAE Version 4 Grade 2 or higher cardiac arrhythmia
- ECG abnormalities e.g., 12-lead ECG showing a baseline QTcF >470 msec.
- a human subject receiving a treatment described herein may be a patient having one or more of the inclusion criteria set forth in Example 3, or not having one or more of the exclusion criteria set forth in Example 3.
- DLBCL such as previously untreated, high risk (IPI or R-IPI ⁇ 3) DLBCL.
- the treatment is maintained continuously using, e.g., the treatment regimens described herein. However, treatment may be terminated when progressive disease develops or unacceptable toxicity occurs.
- the response of subjects with DLBCL to treatment using the methods described herein may be assessed according to the Lugano Response Criteria for Malignant Lymphoma (also referred to as “Lugano criteria” herein) and/or Lymphoma Response to Immunomodulatory Therapy Criteria (also referred to as “LYRIC” herein), as described in Example 3.
- Lugano criteria also referred to as “Lugano criteria” herein
- LYRIC Lymphoma Response to Immunomodulatory Therapy Criteria
- complete response CR
- partial response PR
- SD stable disease
- patients showing disease progression, also referred to as progressive disease (PD), according to the Lugano criteria are further evaluated according to LYRIC. Details regarding the Lugano criteria/classification system, including definitions for complete response, partial response, no response/stable disease, and progressive disease are provided in Cheson et al. J Clin Oncol 2014; 32:3059-68 (see, in particular, Table 3 in Cheson et al., 2014). Details regarding LYRIC are provided in Table 11.
- subjects are treated with the methods described herein until they show disease progression (PD), e.g., as defined by Lugano criteria and/or LYRIC. In one embodiment, subjects are treated with the methods described herein until they show disease progression (PD) as defined by both Lugano criteria and LYRIC. In some embodiments, the subjects are treated with the methods described herein for up to one year total duration of treatment with the bispecific antibody from initiation of R-CHOP.
- PD disease progression
- LYRIC disease progression
- the subjects are treated with the methods described herein for up to one year total duration of treatment with the bispecific antibody from initiation of R-CHOP.
- Subjects treated according to the methods described herein preferably experience improvement in at least one sign of DLBCL.
- improvement is measured by a reduction in the quantity and/or size of measurable tumor lesions.
- lesions can be measured on CT, PET-CT, or MRI films.
- cytology or histology can be used to evaluate responsiveness to a therapy.
- bone marrow aspirate and bone marrow biopsy can be used to evaluate response to therapy.
- the subject treated exhibits a complete response (CR), a partial response (PR), or stable disease (SD), as defined by the Lugano criteria and/or LYRIC (see, e.g., Table 11).
- the methods described herein produce at least one therapeutic effect chosen from prolonged survival, such as progression-free survival or overall survival, optionally compared to another therapy or placebo.
- Cytokine release syndrome can occur when methods are used in human subjects that utilize immune cell- and bispecific antibody-based approaches that function by activation of immune effector cell, such as by engaging CD3 (Lee et al., Biol Blood Marrow Transplant 2019; 25:625-38, which is incorporated herein by reference).
- CRS mitigation is performed together with the methods described herein.
- the selection of a priming dose and/or intermediate dose is performed prior to administering the full dose (e.g., 24 or 48 mg), as described herein.
- CRS can be classified in accordance with standard practice (e.g.
- CRS may include excessive release of cytokines, for example of proinflammatory cytokines, e.g., IL-6, TNF-alpha, or IL-8, that may result in adverse effects like fever, nausea, vomiting and chills.
- cytokines for example of proinflammatory cytokines, e.g., IL-6, TNF-alpha, or IL-8
- proinflammatory cytokines e.g., IL-6, TNF-alpha, or IL-8
- patients may be further subjected to a concomitant treatment, prophylaxis, and/or premedication with, e.g., analgesics, antipyretics, and/or anti-inflammatory drugs to mitigate possible CRS symptoms.
- a concomitant treatment e.g., analgesics, antipyretics, and/or anti-inflammatory drugs to mitigate possible CRS symptoms.
- human subjects in the methods described herein are treated with prophylaxis for CRS.
- the prophylaxis includes the administration of a corticosteroid to the subject.
- the prophylaxis e.g. corticosteroid
- the prophylaxis can also be administered on the subsequent days as well.
- the prophylaxis e.g. corticosteroid
- the prophylaxis corresponding to days 2, 3 and 4 are days 16, 17, and 18 of the cycle.
- the prophylaxis is administered on the day when the bispecific antibody is administered and on subsequent days 2-4.
- the prophylaxis is preferably administered 30-120 minutes prior to said administration of the bispecific antibody.
- the corticosteroid for use in CRS prophylaxis for the methods described herein is preferably prednisone, as it is a component of the R-CHOP regimen.
- the corticosteroid is prednisone.
- prednisone is administered at an intravenous dose of 100 mg, or an equivalent thereof, including an oral dose.
- exemplary corticosteroid equivalents of prednisolone, along with dosage equivalents, which can be used for CRS prophylaxis are shown in Table 5.
- CRS prophylaxis when the bispecific antibody (e.g., epcoritamab) is administered on days when R-CHOP is also administered (e.g., day 1 of each 21-day cycle), it is understood that the R-CHOP regimen already provides the corticosteroid component for the CRS prophylaxis (i.e., prednisone or equivalent), as well as the subsequent administration of corticosteroids in CRS prophylaxis for, e.g., subsequent days 2, 3, and 4.
- the bispecific antibody e.g., epcoritamab
- R-CHOP regimen already provides the corticosteroid component for the CRS prophylaxis (i.e., prednisone or equivalent), as well as the subsequent administration of corticosteroids in CRS prophylaxis for, e.g., subsequent days 2, 3, and 4.
- an additional dose of corticosteroid for CRS prophylaxis may be administered on that day.
- days 2, 3, and 4 after day 1 when R-CHOP and the bispecific antibody were administered, only one dose of prednisone is administered (i.e., the dose serves as both CRS prophylaxis for the bispecific antibody and a component of the R-CHOP regimen).
- prednisone or an equivalent is administered as CRS prophylaxis, e.g., together with premedication (e.g., antihistamine/antipyretic), as described below.
- premedication e.g., antihistamine/antipyretic
- prednisone when prednisone is administered as a part of the R-CHOP regimen on days 1-5 of a 21-day cycle (e.g., cycle 1), and the bispecific antibody is administered on day 1 of that cycle, no additional corticosteroid is administered for CRS prophylaxis, provided that the prednisone component of R-CHOP is administered about 30-120 minutes before the bispecific antibody is administered (i.e., no double dosing of the corticosteroid is performed).
- cycle 1 a 21-day cycle
- a further corticosteroid e.g., prednisone 100 mg or equivalent thereof
- prednisone 100 mg or equivalent thereof is administered as CRS prophylaxis before the bispecific antibody is administered if the prednisone component of R-CHOP is administered more than 120 minutes before the bispecific antibody is administered.
- R-CHOP is withheld on day 1 of a 21-day cycle, and thus the prednisone component of the R-CHOP regimen is not administered to the subject on the same day as the bispecific antibody, then the subject is administered a corticosteroid such as prednisone or its equivalent for CRS prophylaxis.
- human subjects in the methods described herein are treated with premedication to reduce reactions to injections.
- the premedication includes the administration of antihistamines.
- the premedication includes the administration of antipyretics.
- the premedication includes systemic administration of antihistamines and antipyretics.
- An exemplary antihistamine suitable for use in premedication is diphenhydramine.
- the antihistamine for use in premedication is diphenhydramine.
- diphenhydramine is administered at an intravenous or oral dose 50 mg, or an equivalent thereof.
- An exemplary antipyretic suitable for use in premedication is acetaminophen.
- the antipyretic for use in premedication is acetaminophen.
- acetaminophen is administered at an oral dose of 650-1000 mg, or equivalent thereof.
- the premedication is administered on the same day as the bispecific antibody, for example, prior to the injection with the bispecific antibody, e.g., 30-120 minutes prior to administration of the bispecific antibody.
- the antihistamine e.g. diphenhydramine
- the antipyretic is administered on the same day as the bispecific antibody, for example, prior to the injection with the bispecific antibody, e.g., 30-120 minutes prior to administration of the bispecific antibody in an intravenous or oral dose of (or about) 50 mg.
- the antipyretic e.g.
- acetaminophen is administered on the same day as the bispecific antibody, for example, prior to the injection with the bispecific antibody, e.g., 30-120 minutes prior to administration of the bispecific antibody in an oral dose of (or about) 650-1000 mg.
- the antihistamine (e.g. diphenhydramine) and the antipyretic (e.g. acetaminophen) are administered on the same day as the bispecific antibody, for example, prior to the injection with the bispecific antibody, e.g., 30-120 minutes prior to administration of the bispecific antibody in an intravenous or oral dose of (or about) 50 mg and an oral dose of (or about) 650-1000 mg, respectively.
- Premedication and/or prophylaxis for CRS can be administered at least in the initial phase of the treatment.
- premedication and/or prophylaxis is administered during the first four administrations of the bispecific antibody.
- the prophylaxis and/or premedication can be administered as described herein, during the three administrations of the bispecific antibody in the first 21-day cycle and first administration of the bispecific antibody of the second 21-day cycle.
- the prednisone component of the R-CHOP regimen serves as the corticosteroid for prophylaxis of CRS.
- the premedication and/or prophylaxis is administered in cycle 1 and start of cycle 2 of the 21-day cycles.
- the premedication is administered in cycle 1 and start of cycle 2 of the 21-day cycles.
- the prophylaxis is administered in cycle 1 and start of cycle 2 of the 21-day cycles.
- CRS prophylaxis may continue, particularly when the human subject experiences a CRS greater than grade 1.
- premedication may also optionally continue.
- CRS grading can be performed as described in Tables 6 and 7.
- the prophylaxis is administered during the second and third administrations of the bispecific antibody during cycle 2 of the 21-day cycles when the subject experiences CRS greater than grade 1 after the first administration of the bispecific antibody in cycle 2 of the 21-day cycles i.e. the prophylaxis for CRS is continued in the second 21-day cycle when the human subject experiences CRS greater than grade 1 after the first (i.e. fourth administration) administration of the bispecific antibody in cycle 2 (i.e., day 1 of cycle 2 of the 21-day cycles).
- the prophylaxis can be continued during a subsequent cycle, when in the last administration of the bispecific antibody of the previous cycle, the human subject experiences CRS greater than grade 1.
- the prophylaxis is continued in a subsequent cycle, when in the last administration of the bispecific antibody of the previous cycle, the subject experiences CRS greater than grade 1.
- Any premedication may be optionally administered during the second cycle (i.e. cycle 2). Further premedication may be optionally administered during subsequent cycles as well.
- premedication and prophylaxis for CRS is administered, including an antihistamine such as diphenhydramine (e.g., at an intravenous or oral dose 50 mg, or an equivalent thereof), an antipyretic such as acetaminophen (e.g., at an oral dose of 650-1000 mg, or an equivalent thereof), and a corticosteroid such as prednisone (e.g., at an intravenous dose of 100 mg, or an equivalent thereof).
- an antihistamine such as diphenhydramine (e.g., at an intravenous or oral dose 50 mg, or an equivalent thereof)
- an antipyretic such as acetaminophen
- a corticosteroid such as prednisone
- the premedication and prophylaxis is administered 30-120 minutes prior to administration of the bispecific antibody.
- further prophylaxis is administered comprising the systemic administration of a corticosteroid such as prednisone (e.g., at an intravenous dose of 100 mg, or an equivalent thereof).
- a corticosteroid such as prednisone
- the premedication and prophylaxis schedule preferably is administered during the first four administrations of the bispecific antibody, e.g., during the first 21-day cycle and start of the second 21-day cycle of bispecific antibody administration described herein.
- subsequent cycles in case of, e.g., CRS greater than grade 1 occurring during the last administration of the prior cycle, can include the same administration schedule, wherein the premedication as part of the administration schedule is optional.
- the corticosteroid component of the CRS prophylaxis may not be administered to the subject during the first administration of the bispecific antibody, on day 1 and subsequent days 2-4, of each 21-day cycle if prednisone is administered as part of the R-CHOP regimen.
- CRS can be well managed while at the same time effectively controlling and/or treating the DLBCL.
- subjects treated with the methods described herein may experience manageable CRS.
- subjects receiving the treatment described herein may develop CRS of grade 1 as defined in accordance with standard practice.
- subjects may develop manageable CRS of grade 2 as defined in accordance with standard practice.
- subjects receiving the treatments described herein may have manageable CRS of grade 1 or grade 2 during as defined in accordance with standard practice.
- a grade 1 CRS includes a fever to at least 38° C., no hypotension, no hypoxia, and a grade 2 CRS includes a fever to at least 38° C. plus hypotension, not requiring vasopressors and/or hypoxia requiring oxygen by low flow nasal cannula or blow by.
- Such manageable CRS can occur during cycle 1.
- Human subjects receiving the treatments described herein may also have CRS greater than grade 2 during the treatments as defined in accordance with standard practice.
- human subjects receiving the treatments described herein may also have CRS of grade 3 during said treatments as defined in accordance with standard practice.
- Such manageable CRS may further occur during cycle 1 and subsequent cycles.
- Human subjects treated according to the methods described herein may also experience pyrexia, fatigue, and injection site reactions. They may also experience neurotoxicity, partial seizures, agraphia related to CRS, or confusional state related to CRS.
- CRS grading criteria are described in Tables 6 and 7.
- subjects who develop Grade 1 CRS are treated with antibiotics if they present with infection i.e. the subject is administered antibiotics if the subject develops Grade 1 CRS.
- the antibiotics are continued until neutropenia, if present, resolves.
- subjects with Grade 1 CRS who exhibit constitutional symptoms are treated with NSAIDs.
- subjects who develop Grade 2 CRS are treated with intravenous fluid boluses and/or supplemental oxygen.
- subjects who develop Grade 2 CRS are treated with a vasopressor (e.g., norepinephrine).
- subjects with Grade 2 CRS with comorbidities are treated with tocilizumab (a humanized antibody against IL-6 receptor, commercially available as, e.g., ACTEMRA®).
- subjects with Grade 2 CRS are treated with tocilizumab and a steroid.
- the steroid is dexamethasone.
- the steroid is methylprednisolone.
- a subject who presents with concurrent ICANS is administered dexamethasone.
- a second dose of tocilizumab is administered together with a dose of corticosteroids.
- additional cytokine therapy e.g., an anti-IL-6 antibody (e.g., siltuximab) or an IL-1R antagonist (e.g., anakinra) is administered to the subject.
- subjects who develop Grade 3 CRS are treated with vasopressor (e.g., norepinephrine) support and/or supplemental oxygen.
- subjects with Grade 3 CRS are treated with tocilizumab.
- subjects with Grade 3 CRS are treated with tocilizumab in combination with steroids (e.g., dexamethasone or its equivalent of methylprednisolone).
- steroids e.g., dexamethasone or its equivalent of methylprednisolone.
- a subject who presents with concurrent ICANS is administered dexamethasone.
- cytokine therapy e.g., an anti-IL-6 antibody (e.g., siltuximab) or an IL-1R antagonist (e.g., anakinra) is administered to the subject.
- an anti-IL-6 antibody e.g., siltuximab
- an IL-1R antagonist e.g., anakinra
- subjects who develop Grade 4 CRS are treated with vasopressor (e.g., norepinephrine) support and/or supplemental oxygen (e.g., via positive pressure ventilation, such as CPAP, BiPAP, intubation, or mechanical ventilation).
- vasopressor e.g., norepinephrine
- supplemental oxygen e.g., via positive pressure ventilation, such as CPAP, BiPAP, intubation, or mechanical ventilation.
- subjects who develop Grade 4 CRS are administered at least two vasopressors.
- subjects who develop Grade 4 CRS are administered tocilizumab and a steroid (e.g., dexamethasone or its equivalent of methylprednisolone).
- a subject who presents with concurrent ICANS is administered dexamethasone.
- additional cytokine therapy e.g., an anti-IL-6 antibody (e.g., siltuximab) or an IL-1R antagonist (e.g., anakinra) is administered to the subject.
- tocilizumab is switched to an IL-6 antibody (e.g., siltuximab) if the subject is refractory to tocilizumab.
- tocilizumab is switched to an IL-1R antagonist (e.g., anakinra) if the subject is refractory to tocilizumab.
- the human subject receives prophylactic treatment for tumor lysis syndrome (TLS) i.e. the subject is treated with prophylaxis for TLS.
- TLS tumor lysis syndrome
- Classification and grading of tumor lysis syndrome can be performed using methods known in the art, for example, as described in Howard et al. N Engl J Med 2011; 364:1844-54, and Coiffier et al., J Clin Oncol 2008; 26:2767-78.
- prophylaxis (prophylactic treatment) of TLS comprises administering one or more uric acid reducing agents prior to administering the bispecific antibody.
- Exemplary uric acid reducing agents include rasburicase and allopurinol.
- the prophylactic treatment of TLS comprises administering rasburicase. In one embodiment, the prophylactic treatment of TLS comprises administering allopurinol. In one embodiment, the prophylactic treatment of TLS comprises administering allopurinol and allopurinol prior to administering the bispecific antibody. In some embodiments, when the subject shows signs of TLS, supportive therapy, such as rasburicase, may be used.
- supportive therapies include, but are not limited to, (a) premedication with acetaminophen (e.g., 650 mg orally), diphenhydramine (e.g., 50-100 mg intravenously or orally), and steroids, for example, 30-60 minutes prior to starting each rituximab infusion, (b) prophylactic treatment for Pneumocystis carinii pneumonia, (c) CNS prophylaxis according to standard local practice (e.g., methotrexate), (d) low-dose aspirin (e.g., 70-100 mg daily) or another prophylactic antithrombotic treatment for subjects without a prior history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 5 years of initiating treatment and considered to be at standard risk for thrombosis, and/or (e) anticoagulation therapy for subjects with a prior medical
- premedication with acetaminophen e.g., 650 mg orally
- the bispecific antibody used in the methods described herein is administered subcutaneously, and thus is formulated in a pharmaceutical composition such that it is compatible with subcutaneous (s.c.) administration, i.e., having a formulation and/or concentration that allows pharmaceutical acceptable s.c. administration at the doses described herein.
- subcutaneous administration is carried out by injection.
- formulations for DuoBody CD3xCD20 that are compatible with subcutaneous formulation and can be used in the methods described herein have been described previously (see, e.g., WO2019155008, which is incorporated herein by reference).
- the bispecific antibody may be formulated using sodium acetate trihydrate, acetic acid, sodium hydroxide, sorbitol, polysorbate 80, and water for injection, and have a pH of 5.5 or about 5.5.
- the bispecific antibody is provided as a 5 mg/mL or 60 mg/mL concentrate.
- the desired dose of the bispecific antibody is reconstituted to a volume of about 1 mL for subcutaneous injection.
- a suitable pharmaceutical composition for the bispecific antibody can comprise the bispecific antibody, 20-40 mM acetate, 140-160 mM sorbitol, and a surfactant, such as polysorbate 80, and having a pH of 5.3-5.6.
- the pharmaceutical formulation may comprise an antibody concentration in the range of 5-100 mg/mL, e.g., 48 or 60 mg/mL of the bispecific antibody, 30 mM acetate, 150 mM sorbitol, 0.04% w/v polysorbate 80, and have a pH of 5.5.
- Such a formulation may be diluted with, e.g., the formulation buffer to allow proper dosing and subcutaneous administration.
- the volume of the pharmaceutical composition is appropriately selected to allow for subcutaneous administration of the antibody.
- the volume to be administered is in the range of about 0.3 mL to about 3 mL, such as from 0.3 mL to 3 mL.
- the volume to be administered can be 0.5 mL, 0.8 mL, 1 mL, 1.2 mL, 1.5 ml, 1.7 mL, 2 mL, or 2.5 mL, or about 0.5 mL, about 0.8 mL, about 1 mL, about 1.2 mL, about 1.5 ml, about 1.7 mL, about 2 mL, or about 2.5 mL.
- the volume to be administered is 0.5 mL or about 0.5 mL.
- the volume to be administered is 0.8 mL or about 0.8 mL. In some embodiments, the volume to be administered is 1 mL or about 1 mL. In some embodiments, the volume to be administered is 1.2 mL or about 1.2 mL. In some embodiments, the volume to be administered is 1.5 mL or about 1.5 mL. In some embodiments, the volume to be administered is 1.7 mL or about 1.7 mL. In some embodiments, the volume to be administered is 2 mL or about 2 mL. In some embodiments, the volume to be administered is 2.5 mL or about 2.5 mL.
- rituximab is formulated in a pharmaceutical composition comprising pharmaceutically-acceptable excipients for administration (e.g., intravenous administration) in accordance with local standard-of-care practice, e.g., as specified by local guidelines or local product labels.
- rituximab is provided as a sterile, clear, colorless, preservative-free liquid concentrate for intravenous administration.
- rituximab is supplied at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-use vials.
- rituximab is formulated in polysorbate 80 (0.7 mg/mL), sodium citrate dihydrate (7.35 mg/mL), sodium chloride (9 mg/mL), and water, at a pH of 6.5, for injection.
- cyclophosphamide, doxorubicin, vincristine, and prednisone are formulated in a pharmaceutical composition comprising pharmaceutically-acceptable excipients for administration (e.g., intravenous administration) in accordance with local standard-of-care practice, e.g., as specified by local guidelines or local product labels, or as directed by the manufacturer.
- cyclophosphamide, doxorubicin, vincristine, and prednisone are diluted from a stock solution, or reconstituted if in lyophilized form, according to, e.g., instructions in the product label (e.g., with 0.9% saline solution).
- prednisone is formulated in a pharmaceutical composition for oral administration.
- the bispecific antibody used in the methods described herein comprises:
- CDR1, CDR2 and CDR3 regions can be identified from variable heavy and light chain regions using methods known in the art.
- the CDR regions from said variable heavy and light chain regions can be annotated according to IMGT (see Lefranc et al., Nucleic Acids Research 1999; 27:209-12, 1999] and Brochet. Nucl Acids Res 2008; 36:W503-8).
- the bispecific antibody comprises:
- the bispecific antibody comprises:
- the bispecific antibody is a full-length antibody. In some embodiments, the bispecific antibody have an inert Fc region. In some embodiments, the bispecific antibody is a full-length antibody and have an inert Fc region.
- the first binding arm for CD3 is derived from a humanized antibody, e.g., from a full-length IgG1, ⁇ (lambda) antibody such as H1L1 described in WO2015001085, which is incorporated herein by reference, and/or the second binding arm for CD20 is derived from a human antibody, e.g., from a full-length IgG1, ⁇ (kappa) antibody such as clone 7D8 as described in WO2004035607, which is incorporated herein by reference.
- the bispecific antibody may be produced from two half molecule antibodies, wherein each of the two half molecule antibodies comprising, e.g., the respective first and second binding arms set forth in SEQ ID NOs: 24 and 25, and SEQ ID NOs: 26 and 27.
- the half-antibodies may be produced in CHO cells and the bispecific antibodies generated by, e.g., Fab-arm exchange.
- the bispecific antibody is a functional variant of DuoBody CD3xCD20.
- the bispecific antibody comprises (i) a first binding arm comprising a first antigen-binding region which binds to human CD3 ⁇ (epsilon) and comprises a VH region comprising an amino acid sequence which is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 6 or a VH region comprising the amino acid sequence of SEQ ID NO: 6, but with 1, 2, or 3 mutations (e.g., amino acid substitutions), and a VL region comprising an amino acid sequence which is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 7 or a VL region comprising the amino acid sequence of SEQ ID NO: 7, but with 1, 2, or 3 mutations (e.g., amino acid substitutions); and
- the bispecific antibody comprises:
- the bispecific antibody comprises (i) a first binding arm comprising a first antigen-binding region which binds to human CD3 ⁇ (epsilon) and comprises a heavy chain comprising an amino acid sequence which is at least 85%, 90%, 95%, 98%, or 99% identical to SEQ ID NO: 24 or a heavy chain comprising the amino acid sequence of SEQ ID NO: 24, but with 1, 2, or 3 mutations (e.g., amino acid substitutions), and a light chain comprising an amino acid sequence which is at least 85%, 90%, 95%, 98%, or 99% identical to SEQ ID NO: 25 or a light chain region comprising the amino acid sequence of SEQ ID NO: 25, but with 1, 2, or 3 mutations (e.g., amino acid substitutions); and
- the antibody comprises an IgG constant region, such as a human IgG1 constant region, e.g., a human IgG1 constant region as defined in SEQ ID NO: 15, or any other suitable IgG1 allotype.
- the bispecific antibody is a full-length antibody with a human IgG1 constant region.
- the first binding arm of the bispecific antibody is derived from a humanized antibody, preferably from a full-length IgG1, ⁇ (lambda) antibody.
- the first binding arm of the bispecific antibody is derived from a humanized antibody, e.g., from a full-length IgG1, ⁇ (lambda) antibody, and thus comprises a ⁇ light chain constant region. In some embodiments, the first binding arm comprises a ⁇ light chain constant region as defined in SEQ ID NO: 22.
- the second binding arm of the bispecific antibody is derived from a human antibody, preferably from a full-length IgG1, ⁇ (kappa) antibody. In one embodiment the second binding arm of the bispecific antibody is derived from a human antibody, preferably from a full-length IgG1, ⁇ (kappa) antibody, and thus may comprise a ⁇ light chain constant region.
- the second binding arm comprises a ⁇ light chain constant region as defined in SEQ ID NO: 23.
- the first binding arm comprises a ⁇ light chain constant region as defined in SEQ ID NO: 22 and the second binding arm comprises a ⁇ light chain constant region as defined in SEQ ID NO: 23.
- the constant region portion of the bispecific antibody may comprise modifications that allow for efficient formation/production of bispecific antibodies and/or provide for an inert Fc region. Such modifications are well known in the art.
- bispecific antibodies may include, but are not limited to, bispecific antibodies with complementary CH3 domains to force heterodimerization, Knobs-into-Holes molecules (Genentech, WO9850431), CrossMAbs (Roche, WO2011117329), or electrostatically-matched molecules (Amgen, EP1870459 and WO2009089004; Chugai, US201000155133; Oncomed, WO2010129304).
- the bispecific antibody comprises an Fc-region comprising a first heavy chain with a first Fc sequence comprising a first CH3 region, and a second heavy chain with a second Fc sequence comprising a second CH3 region, wherein the sequences of the first and second CH3 regions are different and are such that the heterodimeric interaction between said first and second CH3 regions is stronger than each of the homodimeric interactions of said first and second CH3 regions.
- WO2011131746 and WO2013060867 Genemab
- the bispecific antibody comprises in the first heavy chain (i) the amino acid L in the position corresponding to F405 in the human IgG1 heavy chain constant region of SEQ ID NO: 15, and comprises in the second heavy chain the amino acid R in the position corresponding to K409 in the human IgG1 heavy chain constant region of SEQ ID NO: 15, or vice versa.
- Bispecific antibodies may comprise modifications in the Fc region to render the Fc region inert, or non-activating.
- one or both heavy chains may be modified so that the antibody induces Fc-mediated effector function to a lesser extent relative to the bispecific antibody which does not have the modification.
- Fc-mediated effector function may be measured by determining Fc-mediated CD69 expression on T cells (i.e. CD69 expression as a result of CD3 antibody-mediated, Fc ⁇ receptor-dependent CD3 crosslinking), by binding to Fc ⁇ receptors, by binding to C1q, or by induction of Fc-mediated cross-linking of Fc ⁇ Rs.
- the heavy chain constant region sequence may be modified so that Fc-mediated CD69 expression is reduced by at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 99% or 100% when compared to a wild-type (unmodified) antibody, wherein said Fc-mediated CD69 expression is determined in a PBMC-based functional assay, e.g. as described in Example 3 of WO2015001085. Modifications of the heavy and light chain constant region sequences may also result in reduced binding of C1q to said antibody.
- the reduction may be by at least 70%, at least 80%, at least 90%, at least 95%, at least 97%, or 100%, and C1q binding may be determined, e.g., by ELISA.
- the Fc region which may be modified so that the antibody mediates reduced Fc-mediated T-cell proliferation compared to an unmodified antibody by at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 99% or 100%, wherein said T-cell proliferation is measured in a PBMC-based functional assay.
- amino acid positions that may be modified, e.g., in an IgG1 isotype antibody, include positions L234 and L235.
- the bispecific antibody may comprises a first heavy chain and a second heavy chain, and wherein in both the first heavy chain and the second heavy chain, the amino acid residues at the positions corresponding to positions L234 and L235 in a human IgG1 heavy chain according to Eu numbering are F and E, respectively.
- a D265A amino acid substitution can decrease binding to all Fc ⁇ receptors and prevent ADCC (Shields et al., JBC 2001; 276:6591-604).
- the bispecific antibody may comprise a first heavy chain and a second heavy chain, wherein in both the first heavy chain and the second heavy chain, the amino acid residue at the position corresponding to position D265 in a human IgG1 heavy chain according to Eu numbering is A.
- the amino acids in the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain are F, E, and A, respectively.
- An antibody having these amino acids at these positions is an example of an antibody having an inert Fc region, or a non-activating Fc region.
- the bispecific antibody comprises a first heavy chain and a second heavy chain, wherein in both the first and second heavy chains, the amino acids in the positions corresponding to positions L234, L235, and D265 in the human IgG1 heavy chain constant region of SEQ ID NO: 15 are F, E, and A, respectively.
- the bispecific antibody comprises a first heavy chain and a second heavy chain, wherein in the first heavy chain, the amino acid in the position corresponding to F405 in the human IgG1 heavy chain constant region of SEQ ID NO: 15 is L, and wherein in the second heavy chain, the amino acid in the position corresponding to K409 in the human IgG1 heavy chain constant region of SEQ ID NO: 15 is R, or vice versa.
- the bispecific antibody comprises a first heavy chain and a second heavy chain, wherein (i) in both the first and second heavy chains, the amino acids in the positions corresponding to positions L234, L235, and D265 in the human IgG1 heavy chain constant region of SEQ ID NO: 15 are F, E, and A, respectively, and (ii) in the first heavy chain, the amino acid in the position corresponding to F405 in the human IgG1 heavy chain constant region of SEQ ID NO: 15 is L, and wherein in the second heavy chain, the amino acid in the position corresponding to K409 in the human IgG1 heavy chain constant region of SEQ ID NO: 15 is R, or vice versa.
- bispecific antibodies those which have the combination of three amino acid substitutions L234F, L235E and D265A and in addition the K409R or the F405L mutation, as described above, may be referred to with the suffix “FEAR” or “FEAL”, respectively.
- an amino acid sequence of a wild type IgG1 heavy chain constant region may be identified herein as SEQ ID NO: 15.
- the bispecific antibody may comprise an IgG1 heavy chain constant region carrying the F405L substitution and may have the amino acid sequence set forth in SEQ ID NO: 17 and/or an IgG1 heavy chain constant region carrying the K409R substitution and may have the amino acid sequence set forth in SEQ ID NO: 18, and have further substitutions that render the Fc region inert or non-activating.
- the bispecific antibody comprises a combination of IgG1 heavy chain constant regions, with the amino acid sequence of one of the IgG1 heavy chain constant regions carrying the L234F, L235E, D265A and F405L substitutions (e.g., as set forth in SEQ ID NO: 19) and the amino acid sequence of the other IgG1 heavy chain constant region carrying the L234F, L235E, D265A and K409R substitutions (e.g., as set forth in SEQ ID NO: 20).
- the bispecific antibody comprises heavy chain constant regions comprising the amino acid sequences of SEQ ID NOs: 19 and 20.
- the bispecific antibody used in the methods and uses described herein comprises a first binding arm comprising a heavy chain and a light chain as defined in SEQ ID NOs: 24 and 25, respectively, and a second binding arm comprising a heavy chain and a light chain as defined in SEQ ID NOs: 26 and 27, respectively.
- a first binding arm comprising a heavy chain and a light chain as defined in SEQ ID NOs: 24 and 25, respectively
- a second binding arm comprising a heavy chain and a light chain as defined in SEQ ID NOs: 26 and 27, respectively.
- Such an antibody is referred to herein as DuoBody CD3xCD20.
- variants of such antibodies are contemplated use in the methods and uses as described herein.
- the bispecific antibody comprising a heavy chain and a light chain consisting of the amino acid sequences set forth in SEQ ID NOs: 24 and 25, respectively, and a heavy chain and a light chain consisting of the amino acid sequences set forth in SEQ ID NOs: 26 and 27, respectively.
- the bispecific antibody is epcoritamab (CAS 2134641-34-0), or a biosimilar thereof.
- kits which include a pharmaceutical composition containing a bispecific antibody which binds to CD3 and CD20 in accordance with the invention, such as DuoBody CD3xCD20 or epcoritamab, and a pharmaceutically-acceptable carrier, in a therapeutically effective amount adapted for use in the methods described herein.
- the kits may also include a pharmaceutical composition containing rituximab (e.g., for intravenous administration), cyclophosphamide (e.g., for intravenous administration), doxorubicin (e.g., for intravenous administration), vincristine (e.g., for intravenous administration), and/or prednisone (e.g., for intravenous or oral administration).
- kits optionally also can include instructions, e.g., comprising administration schedules, to allow a practitioner (e.g., a physician, nurse, or patient) to administer the composition or compositions contained therein to a patient with DLBCL.
- a practitioner e.g., a physician, nurse, or patient
- the kit also can include a syringe or syringes.
- kits include multiple packages of the single-dose pharmaceutical compositions each containing an effective amount of the bispecific antibody for a single administration in accordance with the methods described herein. They may also include multiple packages of single dose pharmaceutical compositions containing a dose of rituximab, cyclophosphamide, doxorubicin, vincristine, and/or prednisone in accordance with a standard of care regimen. Instruments or devices necessary for administering the pharmaceutical composition(s) also may be included in the kits.
- a bispecific antibody comprising:
- bispecific antibody of any one of embodiments 1-3 wherein the bispecific antibody is administered once every week (weekly administration).
- bispecific antibody of any one of embodiments 4-9 wherein prior to the weekly administration of 24 mg or 48 mg, a priming dose of the bispecific antibody is administered in cycle 1 of the 21-day cycles.
- bispecific antibody of any one of embodiments 10-12 wherein after administering the priming dose and prior to administering the first weekly dose of 24 mg or 48 mg, an intermediate dose of the bispecific antibody is administered.
- bispecific antibody of any one of embodiments 1-31, wherein the dosing schedule for rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, and the bispecific antibody is as shown in Table 2.
- bispecific antibody of any one of embodiments 1-45 wherein prednisone is administered first, rituximab is administered second, cyclophosphamide is administered third, doxorubicin is administered fourth, vincristine is administered fifth, and the bispecific antibody is administered last if rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, and the bispecific antibody are administered on the same day.
- IPI International Prognostic Index
- CRS cytokine release syndrome
- bispecific antibody of embodiment 51, wherein the prophylaxis comprises administering a corticosteroid to the subject.
- an anti-IL-6 antibody e.g., siltuximab
- bispecific antibody of embodiment 82, wherein the prophylaxis for TLS comprises administering one or more uric acid reducing agents prior to administration of the bispecific antibody.
- bispecific antibody of any one of embodiments 1-84 wherein the subject achieves a complete response, a partial response, or stable disease.
- bispecific antibody of embodiment 88 wherein the first binding arm of the bispecific antibody comprises a ⁇ light chain constant region comprising the amino acid sequence set forth in SEQ ID NO: 22.
- bispecific antibody of embodiment 90 wherein the second binding arm comprises a ⁇ light chain constant region comprising the amino acid sequence set forth in SEQ ID NO: 23.
- bispecific antibody of any one of embodiments 1-93 wherein the bispecific antibody comprises a first heavy chain and a second heavy chain, wherein in both the first and second heavy chains, the amino acids in the positions corresponding to positions L234, L235, and D265 in the human IgG1 heavy chain constant region of SEQ ID NO: 15 are F, E, and A, respectively.
- bispecific antibody of any one of embodiments 1-94 wherein the bispecific antibody comprises a first heavy chain and a second heavy chain, wherein in the first heavy chain, the amino acid in the position corresponding to F405 in the human IgG1 heavy chain constant region of SEQ ID NO: 15 is L, and wherein in the second heavy chain, the amino acid in the position corresponding to K409 in the human IgG1 heavy chain constant region of SEQ ID NO: 15 is R, or vice versa.
- bispecific antibody of any one of embodiments 1-95 wherein the bispecific antibody comprises a first heavy chain and a second heavy chain, wherein
- bispecific antibody of embodiment 96 wherein the bispecific antibody comprises heavy chain constant regions comprising the amino acid sequences of SEQ ID NOs: 19 and 20.
- bispecific antibody of any one of embodiments 1-97 wherein the bispecific antibody comprises a heavy chain and a light chain comprising the amino acid sequences set forth in SEQ ID NOs: 24 and 25, respectively, and a heavy chain and a light chain comprising the amino acid sequences set forth in SEQ ID NOs: 26 and 27, respectively.
- bispecific antibody of any one of embodiments 1-98 wherein the bispecific antibody comprises a heavy chain and a light chain consisting of the amino acid sequence of SEQ ID NOs: 24 and 25, respectively, and a heavy chain and a light chain consisting of the amino acid sequence of SEQ ID NOs: 26 and 27, respectively.
- a method of treating diffuse large B-cell lymphoma (DLBCL) in a human subject comprising administering to the subject a bispecific antibody, and an effective amount of (a) rituximab, (b) cyclophosphamide, (c) doxorubicin, (d) vincristine and (e) prednisone, wherein the a bispecific antibody comprises:
- bispecific antibody is a full-length antibody with a human IgG1 constant region.
- the bispecific antibody comprises a first heavy chain and a second heavy chain, wherein in both the first and second heavy chains, the amino acids in the positions corresponding to positions L234, L235, and D265 in the human IgG1 heavy chain constant region of SEQ ID NO: 15 are F, E, and A, respectively.
- the bispecific antibody comprises a first heavy chain and a second heavy chain, wherein in the first heavy chain, the amino acid in the position corresponding to F405 in the human IgG1 heavy chain constant region of SEQ ID NO: 15 is L, and wherein in the second heavy chain, the amino acid in the position corresponding to K409 in the human IgG1 heavy chain constant region of SEQ ID NO: 15 is R, or vice versa.
- bispecific antibody comprises heavy chain constant regions comprising the amino acid sequences of SEQ ID NOs: 19 and 20.
- the bispecific antibody comprises a heavy chain and a light chain comprising the amino acid sequences set forth in SEQ ID NOs: 24 and 25, respectively, and a heavy chain and a light chain comprising the amino acid sequences set forth in SEQ ID NOs: 26 and 27, respectively.
- bispecific antibody comprises a heavy chain and a light chain consisting of the amino acid sequence of SEQ ID NOs: 24 and 25, respectively, and a heavy chain and a light chain consisting of the amino acid sequence of SEQ ID NOs: 26 and 27, respectively.
- DuoBody-CD3xCD20 is a bsAb recognizing the T-cell antigen CD3 and the B-cell antigen CD20.
- DuoBody-CD3xCD20 triggers potent T-cell-mediated killing of CD20-expressing cells.
- DuoBody-CD3xCD20 has a regular IgG1 structure.
- IgG1-CD3-FEAL Two parental antibodies, IgG1-CD3-FEAL, a humanized IgG1 ⁇ , CD3 ⁇ -specific antibody having heavy and light chain sequences as listed in SEQ ID NOs: 24 and 25, respectively, and IgG1-CD20-FEAR, derived from human IgG1 ⁇ CD20-specific antibody 7D8 having heavy and light chain sequences as listed in SEQ ID NOs: 26 and 27, respectively, were manufactured as separate biological intermediates.
- Each parental antibody contains one of the complementary mutations in the CH3 domain required for the generation of DuoBody molecules (F405L and K409R, respectively).
- the parental antibodies comprised three additional mutations in the Fc region (L234F, L235E and D265A; FEA).
- the parental antibodies were produced in mammalian Chinese hamster ovary (CHO) cell lines using standard suspension cell cultivation and purification technologies.
- DuoBody-CD3xCD20 was subsequently manufactured by a controlled Fab-arm exchange (cFAE) process (Labrijn et al. 2013, Labrijn et al. 2014, Gramer et al. 2013).
- the parental antibodies are mixed and subjected to controlled reducing conditions. This leads to separation of the parental antibodies that, under re-oxidation, re-assemble. This way, highly pure preparations of DuoBody-CD3xCD20 ( ⁇ 93-95%) were obtained. After further polishing/purification, final product was obtained, close to 100% pure.
- the final product was stored at 4° C.
- the product has an international proprietary name of epcoritamab.
- Epcoritamab is prepared (5 mg/mL or 60 mg/mL) as a sterile clear colorless to slightly yellow solution supplied as concentrate for solution for subcutaneous (SC) injection.
- Epcoritamab contains buffering and tonicifying agents. All excipients and amounts thereof in the formulated product are pharmaceutically acceptable for subcutaneous injection products. Appropriate doses are reconstituted to a volume of about 1 mL for subcutaneous injection.
- Example 1 Anti-Tumor Activity of Epcoritamab in the Presence of Anti-CD20 Antibody In Vivo and in NHL Patient-Derived Samples after Anti-CD20 Treatment
- Epcoritamab was found to effectively reduce tumor growth in the xenograft model (NOD-SCID mice injected with CD20-expressing Raji-luc tumor cells and PBMCs), even in the presence of an excess of a rituximab variant with an inert Fc domain (IgG1-RTX-FEAR, containing L234F, L235E, D265A, and K409R mutations).
- Rituximab and IgG1-CD20 compete for CD20 binding even though they bind to a different epitope, indicating that epcoritamab is able to induce effective anti-tumor activity in the presence of circulating anti-CD20 antibodies that can compete for target binding.
- epcoritamab induced T-cell-mediated cytotoxicity in primary DLBCL and follicular lymphoma patient biopsies taken a certain amount of time after administration of an anti-CD20 antibody (Van der Horst et al., Blood (2019) 134 (Supplement_1): 4066). Even in a biopsy taken 2 weeks after administering anti-CD20 antibody, epcoritamab was able to induce up to 40% tumor cell kill.
- CHOP is often used to treat DLBCL and FL. This experiment was performed to test the impact of CHOP components separately to evaluate each component's effect on epcoritamab-induced T-cell-mediated cytotoxicity.
- T cells were pre-incubated with cyclophosphamide, doxorubicin, vincristine, or prednisone for 16 hours and subsequently used in a cytotoxicity assay with epcoritamab and CD20-expressing Daudi cells as target cells (E:T ratio 2:1), in which cyclophosphamide, doxorubicin, vincristine, or prednisone was added in the same concentration as during pre-incubation, respectively.
- Data are presented as percent viable target cells (CD4-CD8-CD22+), normalized to medium control (no Ab, no CHOP component). Since doxorubicin pre-treatment affected the viability of the T cells, not all concentrations of epcoritamab could be tested.
- FIGS. 1 A- 1 D show in the left panels dose response curves for DuoBody-CD3xCD20 for a representative donor, the right panels show the response to a dose of 333 ng/ml of DuoBody-CD3xCD20 for four different donors, with and without various concentrations of the CHOP components.
- T cells pretreated with cyclophosphamide (A), vincristine (C), or prednisone (D) were able to mediate an epcoritamab-induced cytotoxic response against the CD20-expressing target cells, as shown by the dose-dependent cytotoxicity (in the left panels) and the very low percentages of viable B cells left after incubation (in the right panels).
- the remaining T cells pre-treated with doxorubicin were also able to mediate epcoritamab-induced cytotoxicity against target cells indicating that the remaining T cells were functional.
- Epcoritamab as monotherapy is currently in a clinical trial for the treatment of relapsed/refractory (R/R) B-NHL (ClinicalTrials.gov Identifier: NCT03625037).
- R/R B-NHL relapsed/refractory B-NHL
- Preliminary data suggest that the drug is tolerated at doses up to at least 48 mg, including 60 mg, in R/R B-NHL patients, with no dose-limiting toxicities reported.
- the primary objective of the dose escalation part is to evaluate the safety and tolerability of epcoritamab in combination with R-CHOP (endpoints: incidence of dose-limiting toxicities (DLTs), incidence and severity of adverse events (AEs), incidence and severity of changes in laboratory values, and incidence of dose interruptions and delays).
- endpoints incidence of dose-limiting toxicities (DLTs), incidence and severity of adverse events (AEs), incidence and severity of changes in laboratory values, and incidence of dose interruptions and delays).
- Secondary objectives of the dose escalation part include characterizing the PK properties of epcoritamab (endpoints: PK parameters, including clearance, volume of distribution, AUC0-last, AUC0-x, Cmax, Tmax, predose values, and half-life), evaluating pharmacodynamic markers linked to efficacy and the mechanism of action of epcoritamab (endpoints: pharmacodynamic markers in blood samples and within tumor), evaluating immunogenicity (endpoint: incidence of anti-drug antibodies (ADAs) to epcoritamab), and assessing the preliminary anti-tumor activity of epcoritamab in combination with R-CHOP (endpoints: overall response rate (ORR) by Lugano criteria and LYRIC, duration of response (DOR) by Lugano criteria and LYRIC, time to response (TTR) by Lugano criteria and LYRIC, progression free survival (PFS) by Lugano criteria and LYRIC, overall survival (OS), time to next anti-lymphoma therapy (TTNT
- Exploratory objectives of the dose escalation part include assessing potential biomarkers predictive of clinical response to epcoritamab (endpoints: CD3, CD20, and other molecular/phenotypic markers pre-treatment and during treatment, DNA mutation status, and gene profile).
- the primary objective of the expansion part is to assess the preliminary anti-tumor activity of epcoritamab in combination with R-CHOP (endpoint: ORR by Lugano criteria).
- Secondary objectives of the expansion part include evaluating the preliminary anti-tumor activity of epcoritamab in combination with R-CHOP (endpoints: endpoints: DOR by Lugano criteria and LYRIC, TTR by Lugano criteria and LYRIC, PFS by Lugano criteria and LYRIC, ORR by LYRIC, OS, TTNT, and rate and duration of minimal residual disease (MRD) negativity), further evaluating the safety and tolerability of epcoritamab in combination with R-CHOP (endpoints: incidence and severity of changes in laboratory values, and incidence of dose interruptions and delays), characterizing the PK properties of epcoritamab (PK parameters, including clearance, volume of distribution, AUC0-last, AUC0-x, Cmax, Tmax, predose values, and half-life), evaluating pharmacodynamic markers linked to efficacy and mechanism of action of epcoritamab (endpoints: pharmacodynamic markers in blood samples and within tumor), and evaluating immunogenicity (endpoint: incidence
- Exploratory objectives of the expansion part include assessing potential biomarkers predictive of clinical response to epcoritamab (endpoints: expression of CD20 in tumors, evaluation of molecular and genetic tumor markers, immune populations, phenotype and function in tumors and blood, and DNA mutation status and gene profile), and evaluating patient-reported outcomes (PROs) (endpoint: changes in lymphoma symptoms and general health status as evaluated by the FACT-Lym).
- the trial is conducted in 2 parts: dose escalation (Part 1) and expansion (Part 2). Subjects participate in only one part.
- a schematic of the overall trial design is shown in FIG. 2 . Both parts consist of a screening period, a treatment period, a safety follow-up period, and a survival follow-up period.
- the Part 1 dose escalation assesses the initial safety, tolerability, and clinical activity of epcoritamab in combination with R-CHOP.
- Epcoritamab is initially be administered in combination with R-CHOP in a 3-subject cohort. DLTs are evaluated during the first 28 days. Depending on the number of DLTs observed in the initial 3 subjects, administration of epcoritamab (full dose: 48 mg or 24 mg) in combination with R-CHOP is performed in an additional 3 subjects as shown in FIG. 3 .
- epcoritamab is administered (with the dosing regimen determined in the dose-escalation part) in combination with R-CHOP.
- the expansion will include 20 subjects in order to evaluate the preliminary clinical activity of the combination, in addition to safety, tolerability, PK, pharmacodynamic, and immunogenicity data.
- epcoritamab is administered as a subcutaneous (SC) injection (24 mg or 48 mg; step-up dosing) for up to one year total duration of treatment with the bispecific antibody from initiation of R-CHOP, with 6 (Table 2a), or 8 (Table 2b) of the cycles in combination with R-CHOP, as follows:
- a step-up dosing method is used for epcoritamab to mitigate the potential for CRS: priming dose (0.16 mg) on cycle 1 day 1, followed by intermediate dose (0.8 mg) on cycle 1 day 8, full dose (24 mg or 48 mg) on cycle 1 day 15, and full dose in subsequent cycles.
- Rituximab 375 mg/m 2
- Cyclophosphamide 750 mg/m 2
- Doxorubicin 50 mg/m 2
- Vincristine (1.4 mg/m 2 , with a recommended cap of 2 mg) is administered intravenously on day 1 once every three weeks (Q3 W) of cycles 1-6 or 1-8.
- Prednisone (100 mg/day) is administered intravenously or orally on five consecutive days (days 1-5) every three weeks (Q3 W) of cycles 1-6 or 1-8.
- Pre-Meds Pre-medications
- Prednisone As described in Table 4 component of R-CHOP may serve as corticosteriod premedication/CRS prophylaxis
- Prednisone 100 mg
- Cyclophosphamide* 750 mg/m 2
- Doxorubicin* 50 mg/m 2 (hydroxydaunomycin)
- Vincristine* Oncovin ®
- Epcoritamab 24 mg or 48 mg *Intravenous components of R-CHOP may be administered over 2 days, with subsequent epcoritamab administration on day 2.
- Prednisone in the R-CHOP regimen serves as the corticosteroid component of the CRS prophylaxis regimen on days 1-4 of cycle 1 of the 21-day cycles, but not days 8-11 and 15-18 of cycle 1 of the 21-day cycles, which will use prednisolone 100 mg or equivalent for CRS prophylaxis.
- CRS prophylaxis is optional.
- Prednisone administration can be either intravenous or oral route with recommended dose or equivalent.
- epcoritamab dose is administered more than 24 h after the start of R-CHOP, the premedication is administered prior to epcoritamab dose and corticosteroid prophylaxis is continued for 3 days following the epcoritamab administration.
- CRS is graded according to the ASTCT grading for CRS (Tables 6 and 7), and for treatment of CRS, subjects should receive supportive care.
- Supportive care can include, but is not limited to,
- organ toxicities or constitutional symptoms associated with CRS may be graded according to CTCAE but they do not influence CRS grading.
- Fever is defined as temperature ⁇ 38.0° C. not attributable to any other cause, with or without constitutional symptoms (eg, myalgia, arthralgia, malaise).
- constitutional symptoms eg, myalgia, arthralgia, malaise.
- CRS grading is driven by hypotension and/or hypoxia.
- CRS grade is determined by the more severe event: hypotension or hypoxia not attributable to any other cause.
- a subject with temperature of 39.5° C., hypotension requiring 1 vasopressor, and hypoxia requiring low-flow nasal cannula is classified as grade 3 CRS.
- Both systolic blood pressure and mean arterial pressure are acceptable for blood pressure measurement. No specific limits are required, but hypotension should be determined on a case-by-case basis, accounting for age and the subject's individual baseline, i.e., a blood pressure that is below the normal expected for an individual in a given environment.
- 3 Intubation of a subject without hypoxia for the possible neurologic compromise of a patent airway alone or for a procedure is not by definition grade 4 CRS.
- vasopressor no vasopressor
- hypoxia Administer oxygen by high-flow nasal cannula (>6 L/min), facemask, non- breather mask, or Venturi mask.
- Tocilizumab Yes ⁇ .
- Steroids Consider ⁇ . 4 Fever: As per grade 1.
- Hypotension Immediate clinical evaluation and intervention is warranted.
- Hypoxia Positive pressure (e.g. CPAP, BiPAP, intubation, and mechanical ventilation).
- Tocilizumab Yes ⁇ .
- Steroids Yes ⁇ .
- ⁇ Tocilizumab anti-IL-6R remains the only first-line anticytokine therapy approved for CRS. If there is no improvement in symptoms within 6 hours, or if the patient starts to deteriorate after initial improvement, a second dose of tocilizumab should be administered along with a dose of corticosteroids.
- anticytokine therapy such as siltuximab (anti-IL-6) or anakinra (anti-IL-1R) may be considered.
- anti-IL-6 siltuximab
- anti-IL-1R anakinra
- dexamethasone should be preferred.
- Source (Varadarajan I, Kindwall-Keller T L, Lee D W (2020). Management of cytokine release syndrome.
- Chimeric antigen receptor T-cell therapies for cancer (Chapter 5). Elsevier 2020)
- tumor lysis syndrome For prophylactic treatment of tumor lysis syndrome, subjects receive hydration and uric acid reducing agents prior to the administration of epcoritamab. If signs of tumor lysis syndrome (TLS) occur, supportive therapy, including rasburicase, is used.
- TLS tumor lysis syndrome
- Dose modifications for rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone should be done in accordance with the respective product labels in situations that differ from dose modification recommendations provided below.
- Treatment-emergent adverse events of R-CHOP combination therapy predominantly comprise hematologic toxicities (such as neutropenia, leucopenia, thrombocytopenia, and anemia).
- hematologic toxicities such as neutropenia, leucopenia, thrombocytopenia, and anemia.
- Nonhematologic disorders such as asthenia, sensory disturbance, mucositis, alopecia, sepsis, dyspnea, back pain, hyperglycemia, hypersensitivity, and cardiac disorders have all also been observed when treatment with R-CHOP has been administered. It is not always easy to assess the role of any 1 agent in these events; therefore, it is at the investigator's discretion to decide if 1 or more agents are causal.
- the start of a new cycle may be delayed on a weekly basis until recovery of toxicity to a level allowing continuation of therapy.
- a subject whose cycle is delayed should be assessed weekly for resolution of toxicity. If toxicity persists after a 2-week cycle delay that is related to 1 specific drug (vincristine, doxorubicin, etc.), the offending drug should continue to be withheld and the new cycle should be started with the remaining drugs. If R-CHOP chemotherapy is delayed, treatment with epcoritamab should be continued during the delay phase (provided the reason for delay is not toxicity potentially related to epcoritamab therapy).
- Subjects who discontinue any component of R-CHOP without disease progression will continue epcoritamab for up to 16 cycles or until one or more of the following discontinuation criteria are met: (a) unacceptable AE, (b) subject non-compliance, (c) pregnancy, (d) subject request to discontinue treatment, (e) clinical progression, of (f) radiographic evidence of disease progression.
- Rituximab should be held for any Grade 4 toxicity or for any rituximab-related, clinically significant, unmanageable Grade 3 adverse event. Rituximab should be held until the adverse event returns to baseline or resolves completely.
- Dose adjustments for cyclophosphamide follow the local prescribing information.
- the most common adverse events experienced with cyclophosphamide are hematological toxicities; myelosuppression with leucopenia, anemia, and thrombocytopenia may occur.
- the lowest leukocyte and platelet levels occur in the first to second week after treatment is started. Recovery usually occurs within 3 to 4 weeks after treatment is started.
- hemorrhagic cystitis and hematuria may occur. These may necessitate interruption of dosing.
- the dose of cyclophosphamide should be adjusted on Day 1 of the subsequent cycle of dosing when subjects develop hematological toxicities thought to be causally related to cyclophosphamide.
- Dose adjustments for doxorubicin follow the provided prescribing information.
- the recommended lifetime cumulative dose limit of doxorubicin is 450 to 550 mg/m 2 .
- the maximum dose given for each subject is 300 to 400 mg/m 2 , depending on the number of cycles given.
- Dose-limiting toxicities of doxorubicin therapy are mucositis, myelosuppression, and cardiotoxicity. Myelosuppression includes leucopenia, thrombocytopenia, and anemia, reaching nadir at 10 to 14 days after treatment.
- the dose of doxorubicin should be adjusted on Day 1 of the subsequent cycle of dosing when subjects develop hematological toxicities thought to be causally related to doxorubicin (see Table 8 above).
- Cardiotoxicity as an arrhythmia can occur directly after administration and ECG changes may last up to 2 weeks after administration. Cardiotoxicity may, however, occur several weeks or months after administration.
- Doxorubicin is metabolized by the liver and excreted in bile. Impairment of liver function results in slower excretion of the drug and consequently increased retention and accumulation in the plasma and tissues, resulting in enhanced clinical toxicity. Doxorubicin dosage is reduced if hepatic function is impaired, as shown in Table 9.
- vincristine dosage is reduced if hepatic function is impaired, as shown in Table 10.
- Vincristine doses is re-escalated when hyperbilirubinemia improves. These dose reductions are not required in subjects with Gilbert syndrome and in cases where the increase of bilirubin is due to non-hepatic reasons.
- Neurologic toxicity is the most common adverse event experienced with vincristine and is related to dose and age. In case of severe neurotoxicity (Grade ⁇ 3), vincristine should not be administered, especially if there are signs of paresthesia or paresis. For grade 3 neuropathy, treatment may be resumed at 50% of the dose when symptoms subside. Vincristine is reduced by 25% for any episode of ileus/constipation requiring hospitalization. Vincristine is permanently discontinued for Grade 4 neuropathy of any type.
- prednisone or equivalent
- Subjects administered high-dose prednisone or equivalent are monitored carefully as there is a relatively higher risk of developing or exacerbating some conditions (e.g., bacterial infections, viral infections, systemic mycoses, hypertension, diabetes mellitus, and gastrointestinal conditions such as peptic ulcers, pancreatitis, and diverticulitis).
- some conditions e.g., bacterial infections, viral infections, systemic mycoses, hypertension, diabetes mellitus, and gastrointestinal conditions such as peptic ulcers, pancreatitis, and diverticulitis.
- the dose is adjusted to a level specific to that subject but should be no less than prednisone 80 mg per day (so that the subject still receives a high dose of corticosteroid).
- a subject may not tolerate sudden steroid withdrawal after 5 days of therapy. In such an instance, a tapering regimen of is indicated.
- Demographic details of subjects are collected, as is information such as date of lymphoma diagnosis, Ann Arbor Staging at diagnosis, including constitutional symptoms (B symptoms), and prior evidence of CD20 positivity. Medical history, information regarding prior and concomitant medications, concomitant procedures, and prior cancer therapies and surgeries (including prior anti-cancer therapy for NHL, such as surgery, radiotherapy, chemo-radiotherapy, and systemic treatment regimens), are also collected.
- Eligible subjects have at least 1 measurable site of disease (as indicated in the inclusion criteria) for disease evaluations.
- Measurable sites of lymphoma are defined as lymph nodes, lymph node masses, or extranodal sites. Measurements are determined by imaging evaluation, with up to 6 measurable sites followed as target lesions for each subject. Sites not measurable as defined above are considered assessable by objective evidence of disease (i.e., radiographic imaging, physical examination, or other procedures). Examples of assessable disease include, e.g., bone marrow involvement, bone lesions, effusions, or thickening of bowel wall.
- Two fresh core tumor biopsies are collected before treatment with epcoritamab (during the screening period) and 2 fresh core tumor biopsies at the start of cycle 2 day 15 ( ⁇ 1 week) for all subjects with accessible tumors.
- An archival tumor biopsy if collected within 3 months prior to enrollment, is acceptable if a fresh biopsy at screening cannot be collected.
- the biopsy can be a whole lymph node or a core biopsy.
- Tumor biopsies should be FFPE. Tumor biopsies are examined for MRD assessment and exploratory biomarkers.
- An FDG PET-CT scan (or CT/MRI and FDG PET when PET-CT scan not available) is performed during Screening.
- all subsequent disease assessments include FDGPET using the 5-point scale described in Barrington et al. ( J Clin Oncol 2014; 32:3048-58; Score 1: No uptake; Score 2: Uptake ⁇ mediastinum; Score 3: Update >mediastinum but ⁇ liver; Score 4: Uptake moderately higher than liver; Score 5: Uptake markedly higher than liver and/or new lesions; Score X: new areas of update unlikely to be related to lymphoma).
- a standalone diagnostic CT/MRI and a standard FDGPET is performed. Subjects who are intolerant of IV CT contrast agents undergo CT scans with oral contrast.
- MRI can be used to evaluate sites of disease that cannot be adequately imaged using CT or for subjects intolerant of CT contrast agents.
- the MRI is obtained at screening and at all subsequent response evaluations.
- a bone marrow biopsy (archival or fresh), with or without aspirate, is obtained at screening for all patients to document bone marrow involvement with lymphoma.
- a bone marrow biopsy obtained as routine SOC may be used if taken up to 42 days before first dose of epcoritamab. If bone marrow aspirate is obtained, determination of bone marrow involvement can be confirmed by flow cytometry.
- a bone marrow biopsy is taken (1) at screening, (2) for subjects with bone marrow involvement at screening who later achieve CR by imaging—bone marrow evaluation includes morphological examination and either flow cytometry or IHC, if warranted, to confirm the presence or absence (complete remission) of lymphoma; (3) for subjects with bone marrow involvement documented at screening who later achieve CR by imaging—a portion of the aspirate collected to confirm CR will be used for MRD assessments.
- MRD is assessed by tracking the presence of DNA that encodes the B cell receptor (BCR) expressed specifically by the cancer cells.
- BCR B cell receptor
- the DNA sequence of this BCR is identified by tumor biopsy submitted at screening. After the start of treatment, blood samples are taken at fixed timepoints and at the time of CR to assess whether the amount of cancer DNA is declining, as a potential measure of (early) response, and to assess MRD.
- a portion of the aspirate collected to confirm CR is used to assess MRD.
- Target lesions for the Lugano criteria include up to 6 of the largest dominant nodes, nodal masses, or other lymphomatous lesions that are measurable in two diameters and are preferably from different body regions representative of the subject's overall disease burden, including mediastinal and retroperitoneal disease, where applicable.
- a measurable node is >15 mm in longest diameter (LDi).
- Measurable extranodal disease may be included in the six representative target lesions.
- measurable extranodal lesions should be >10 mm in LDi.
- All other lesions may be followed as non-target lesions (e.g., cutaneous, GI, bone, spleen, liver, kidneys, pleural or pericardial effusions, ascites, bone, bone marrow).
- non-target lesions e.g., cutaneous, GI, bone, spleen, liver, kidneys, pleural or pericardial effusions, ascites, bone, bone marrow).
- Lesions may split or may become confluent over time.
- the individual product of the perpendicular diameters (PPDs) of the nodes should be summed together to represent the PPD of the split lesion; this PPD is added to the sum of the PPDs of the remaining lesions to measure response. If subsequent growth of any or all of these discrete nodes occurs, the nadir of each individual node is used to determine progression.
- the PPD of the confluent mass should be compared with the sum of the PPDs of the individual nodes, with more than 50% increase in PPD of the confluent mass compared with the sum of individual nodes necessary to indicate progressive disease (PD).
- the LDi and smallest diameter (SDi) are no longer needed to determine progression.
- cancer immunotherapies may result in early apparent radiographic progression (including the appearance of new lesions), followed by a delayed response. As this initial increase in tumor size might be caused by immune-cell infiltration in the setting of a T-cell response, this progression may not be indicative of true disease progression and is therefore called “pseudoprogression” (Wolchok et al., Clin Cancer Res 2009; 15:7412-20).
- Lugano response assessment criteria (Cheson et al., J Clin Oncol 2014; 32:3059-68) does not take pseudoprogression into account, and there is a significant risk of premature discontinuation of a potentially efficacious immunomodulatory drug following the observation of an atypical response.
- Atypical responses are characterized either by the early progression of existing lesions, later followed by response, or by the development of new lesions, with or without tumor shrinkage elsewhere.
- LYRIC is a modification of the Lugano response assessment criteria, which has been adapted to immune-based therapies, and it implements a new, mitigating response category: the “indeterminate response” (IR) designation (Cheson et al., Blood 2016; 128:2489-96). This IR designation was introduced to potentially identify “atypical response” cases until confirmed as flare/pseudoprogression or true PD by either biopsy or subsequent imaging.
- IR indeterminate response
- a subject could fulfill criteria for both IR(1) or IR(2) and IR(3): for example, there could be a new FDG-avid lesion in the absence of overall progression (IR[2]), and, at the same time, increase in FDG uptake of a separate lesion (IR[3]).
- the designation of IR(1) or IR (2) should take priority (e.g., IR[2] in the above example).
- Subjects categorized as having any of the IR types receive repeat imaging after an additional 12 weeks (or earlier if clinically indicated). At that time, response should be re-evaluated, and the subject should be considered to have true PD with the following considerations:
- Safety is assessed by measuring adverse events, laboratory test results, ECGs, vital sign measurements, physical examination findings, and ECOG performance status. Also assessed are immune effector cell-associated neurotoxicity syndrome (e.g., as described by Lee et al., Biol Blood Marrow Transplant 2019; 25:625-638), constitutional symptoms (B symptoms), tumor flare reaction, and survival.
- immune effector cell-associated neurotoxicity syndrome e.g., as described by Lee et al., Biol Blood Marrow Transplant 2019; 25:625-638
- constitutional symptoms B symptoms
- tumor flare reaction and survival.
- Patient-reported outcomes are evaluated using the FACT-Lym health-related quality of life (QOL) questionnaire, which assesses QOL in lymphoma patients.
- QOL quality of life
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/025,203 US20240034812A1 (en) | 2020-09-10 | 2021-09-10 | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063076797P | 2020-09-10 | 2020-09-10 | |
US18/025,203 US20240034812A1 (en) | 2020-09-10 | 2021-09-10 | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
PCT/EP2021/075016 WO2022053654A1 (en) | 2020-09-10 | 2021-09-10 | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
Publications (1)
Publication Number | Publication Date |
---|---|
US20240034812A1 true US20240034812A1 (en) | 2024-02-01 |
Family
ID=77924348
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/025,203 Pending US20240034812A1 (en) | 2020-09-10 | 2021-09-10 | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
US17/558,430 Active US11845805B2 (en) | 2020-09-10 | 2021-12-21 | Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma |
US18/500,799 Pending US20240301078A1 (en) | 2020-09-10 | 2023-11-02 | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/558,430 Active US11845805B2 (en) | 2020-09-10 | 2021-12-21 | Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma |
US18/500,799 Pending US20240301078A1 (en) | 2020-09-10 | 2023-11-02 | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
Country Status (11)
Country | Link |
---|---|
US (3) | US20240034812A1 (es) |
EP (1) | EP4210747A1 (es) |
JP (1) | JP2023541860A (es) |
KR (1) | KR20230066583A (es) |
CN (1) | CN116472058A (es) |
AU (1) | AU2021340232A1 (es) |
BR (1) | BR112023004321A2 (es) |
CA (1) | CA3192251A1 (es) |
IL (1) | IL301085A (es) |
MX (1) | MX2023002545A (es) |
WO (1) | WO2022053654A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2021267402A1 (en) * | 2020-05-08 | 2022-11-24 | Genmab A/S | Bispecific antibodies against CD3 and CD20 |
BR112023004327A2 (pt) | 2020-09-10 | 2023-04-04 | Genmab As | Método para tratar leucemia linfocítica crônica em um sujeito humano |
AU2021341509A1 (en) | 2020-09-10 | 2023-04-13 | Genmab A/S | Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma |
MX2023002542A (es) | 2020-09-10 | 2023-03-15 | Genmab As | Anticuerpo biespecifico contra cumulo de difirenciacion 3 (cd3) y cumulo de difirenciacion 20 (cd20) en terapia combinada para el tratamiento del linfoma difuso de celulas b grandes. |
US20230312758A1 (en) | 2020-09-10 | 2023-10-05 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
WO2023144306A1 (en) * | 2022-01-28 | 2023-08-03 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
WO2024006925A2 (en) * | 2022-07-01 | 2024-01-04 | Nkarta, Inc. | Dosing regimens for cd19-directed cancer immunotherapy |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
ATE276199T1 (de) | 1999-02-03 | 2004-10-15 | Biosante Pharmaceuticals Inc | Methoden zur herstellung von therapeutische kalzium-phosphat partikeln |
US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
KR20040088572A (ko) | 2002-03-01 | 2004-10-16 | 이뮤노메딕스, 인코오포레이티드 | 제거율 증강을 위한 양특이성 항체 점 돌연변이들 |
PT1523496E (pt) | 2002-07-18 | 2011-09-29 | Merus B V | Produção de misturas de anticorpos de forma recombinante |
WO2004024655A2 (en) | 2002-09-12 | 2004-03-25 | Avanir Pharmaceuticals | Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation |
CN101928344B (zh) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
KR20060041205A (ko) | 2003-07-01 | 2006-05-11 | 이뮤노메딕스, 인코오포레이티드 | 양특이성 항체들의 다가 담체들 |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
JP5848861B2 (ja) | 2004-04-20 | 2016-01-27 | ジェンマブ エー/エスGenmab A/S | Cd20に対するヒトモノクローナル抗体 |
WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
EP1973576B1 (en) | 2005-11-28 | 2019-05-15 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
KR101516823B1 (ko) | 2006-03-17 | 2015-05-07 | 바이오겐 아이덱 엠에이 인코포레이티드 | 안정화된 폴리펩티드 조성물 |
WO2007110205A2 (en) | 2006-03-24 | 2007-10-04 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
CN104497143B (zh) | 2007-03-29 | 2020-08-25 | 健玛保 | 双特异性抗体及其制造方法 |
JP5456658B2 (ja) | 2007-03-30 | 2014-04-02 | メディミューン,エルエルシー | 抗体製剤 |
ES2432792T5 (es) | 2007-04-03 | 2023-01-16 | Amgen Res Munich Gmbh | Dominio de unión a CD3-épsilon específico de especies cruzadas |
WO2008145141A1 (en) | 2007-05-31 | 2008-12-04 | Genmab A/S | Method for extending the half-life of exogenous or endogenous soluble molecules |
CA2691434C (en) | 2007-06-21 | 2020-07-21 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
EP2535350B1 (en) | 2007-09-26 | 2018-01-24 | UCB Biopharma SPRL | Dual specificity antibody fusions |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
EP2235064B1 (en) | 2008-01-07 | 2015-11-25 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
JP2009212059A (ja) | 2008-03-06 | 2009-09-17 | Toshiba Corp | 電動軽車両のバッテリ装置 |
WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
JP5397668B2 (ja) | 2008-09-02 | 2014-01-22 | ソニー株式会社 | 記憶素子および記憶装置 |
AU2009299794B2 (en) | 2008-10-01 | 2015-08-13 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
US8927694B2 (en) | 2008-11-18 | 2015-01-06 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
RU2744176C2 (ru) | 2008-12-19 | 2021-03-03 | Макродженикс, Инк. | Ковалентные диантитела и их применение |
MX2011009810A (es) | 2009-03-27 | 2011-09-30 | Zymogenetics Inc | Composiciones y metodos para usar proteinas de union multiespecificas que comprenden una combinacion anticuerporeceptor. |
ES2708124T3 (es) | 2009-04-27 | 2019-04-08 | Oncomed Pharm Inc | Procedimiento para preparar moléculas heteromultiméricas |
KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
UY32808A (es) | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
EA030792B1 (ru) | 2009-11-30 | 2018-09-28 | Янссен Байотек, Инк | МУТИРОВАННЫЕ Fc АНТИТЕЛ С УСТРАНЕННЫМИ ЭФФЕКТОРНЫМИ ФУНКЦИЯМИ |
RU2016105962A (ru) | 2009-12-04 | 2018-11-23 | Дженентек, Инк. | Мультиспецифические антитела, аналоги антител, композиции и способы |
JP5856073B2 (ja) | 2009-12-29 | 2016-02-09 | エマージェント プロダクト デベロップメント シアトル, エルエルシー | Ron結合構築体およびその使用方法 |
AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
CN103097417B (zh) | 2010-04-20 | 2019-04-09 | 根马布股份公司 | 含异二聚体抗体fc的蛋白及其制备方法 |
JP6022444B2 (ja) | 2010-05-14 | 2016-11-09 | ライナット ニューロサイエンス コーポレイション | ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法 |
ES2537207T3 (es) | 2010-08-16 | 2015-06-03 | Novimmune S.A. | Métodos para la generación de anticuerpos multiespecíficos y multivalentes |
WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
CN103068847B (zh) | 2010-08-24 | 2019-05-07 | 罗切格利卡特公司 | 可活化的双特异性抗体 |
AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
PL2647707T3 (pl) | 2010-11-30 | 2019-02-28 | Chugai Seiyaku Kabushiki Kaisha | Środek terapeutyczny wywołujący cytotoksyczność |
WO2012143524A2 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
SG10201509588TA (en) | 2011-05-21 | 2015-12-30 | Macrogenics Inc | CD3-Binding Molecules Capable Of Binding To Human And Non-Human CD3 |
CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
PE20141521A1 (es) | 2011-08-23 | 2014-10-25 | Roche Glycart Ag | Moleculas biespecificas de union a antigeno activadoras de celulas t |
HUE044633T2 (hu) | 2011-10-27 | 2019-11-28 | Genmab As | Heterodimer fehérjék elõállítása |
MX370199B (es) | 2012-02-16 | 2019-12-05 | Santarus Inc | Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a). |
SI2838918T1 (sl) | 2012-04-20 | 2019-11-29 | Merus Nv | Postopki in sredstva za proizvodnjo heterodimernih IG-podobnih molekul |
EP2869845B1 (en) | 2012-07-06 | 2019-08-28 | Genmab B.V. | Dimeric protein with triple mutations |
DK2869845T3 (da) | 2012-07-06 | 2019-12-09 | Genmab Bv | Dimert protein med tredobbelte mutationer |
JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
US9963512B2 (en) | 2012-11-21 | 2018-05-08 | Pharmabcine Inc. | Dual-target antibody targeting VEGFR-2 and DLL4, and pharmaceutical composition including same |
WO2014131711A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
CN105143270B (zh) | 2013-02-26 | 2019-11-12 | 罗切格利卡特公司 | 双特异性t细胞活化抗原结合分子 |
KR102363220B1 (ko) | 2013-07-05 | 2022-02-15 | 젠맵 에이/에스 | 인간화 또는 키메라 cd3 항체 |
US20160355588A1 (en) | 2013-07-12 | 2016-12-08 | Zymeworks Inc. | Bispecific CD3 and CD19 Antigen Binding Constructs |
WO2015095392A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
US20150225479A1 (en) | 2014-02-12 | 2015-08-13 | Sanofi | Anti-IL-4/Anti-IL-13 Bispecific Antibody/Polyglutamate Formulations |
TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
KR102614189B1 (ko) | 2014-11-17 | 2023-12-18 | 리제너론 파아마슈티컬스, 인크. | Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법 |
SG11201705496SA (en) | 2015-01-08 | 2017-08-30 | Genmab As | Bispecific antibodies against cd3 and cd20 |
US20160199399A1 (en) | 2015-01-09 | 2016-07-14 | Medical Prognosis Institute A/S | Methods for predicting drug responsiveness in cancer patients |
CN104922688A (zh) | 2015-02-10 | 2015-09-23 | 昆明贵研药业有限公司 | 奥沙利铂的环糊精复合物及制备方法 |
UA128057C2 (uk) | 2015-07-15 | 2024-03-27 | Ґенмаб А/С | Гуманізоване або химерне антитіло, яке зв'язує cd3 людини |
EP3464370A1 (en) | 2016-06-01 | 2019-04-10 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma |
US11466094B2 (en) | 2016-11-15 | 2022-10-11 | Genentech, Inc. | Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies |
BR112019022229A2 (pt) | 2017-04-27 | 2020-05-12 | Astrazeneca Ab | Compostos de anilinoquinazolina c5 e seu uso no tratamento do câncer |
WO2019155008A1 (en) | 2018-02-09 | 2019-08-15 | Genmab A/S | Pharmaceutical compositions comprising bispecific antibodies directed against cd3 and cd20 and their uses |
PT3886875T (pt) | 2018-11-30 | 2024-06-27 | Juno Therapeutics Inc | Métodos para tratamento utilizando terapia celular adotiva |
EP4013509A1 (en) | 2019-08-15 | 2022-06-22 | Genmab A/S | Pharmaceutical compositions comprising bispecific antibodies directed against cd3 and cd20 and their uses |
AU2021267402A1 (en) | 2020-05-08 | 2022-11-24 | Genmab A/S | Bispecific antibodies against CD3 and CD20 |
US20230312758A1 (en) | 2020-09-10 | 2023-10-05 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
AU2021341509A1 (en) | 2020-09-10 | 2023-04-13 | Genmab A/S | Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma |
BR112023004327A2 (pt) | 2020-09-10 | 2023-04-04 | Genmab As | Método para tratar leucemia linfocítica crônica em um sujeito humano |
WO2022053658A1 (en) | 2020-09-10 | 2022-03-17 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
MX2023002542A (es) | 2020-09-10 | 2023-03-15 | Genmab As | Anticuerpo biespecifico contra cumulo de difirenciacion 3 (cd3) y cumulo de difirenciacion 20 (cd20) en terapia combinada para el tratamiento del linfoma difuso de celulas b grandes. |
-
2021
- 2021-09-10 AU AU2021340232A patent/AU2021340232A1/en active Pending
- 2021-09-10 CA CA3192251A patent/CA3192251A1/en active Pending
- 2021-09-10 WO PCT/EP2021/075016 patent/WO2022053654A1/en active Application Filing
- 2021-09-10 KR KR1020237011631A patent/KR20230066583A/ko unknown
- 2021-09-10 MX MX2023002545A patent/MX2023002545A/es unknown
- 2021-09-10 BR BR112023004321A patent/BR112023004321A2/pt unknown
- 2021-09-10 EP EP21777974.3A patent/EP4210747A1/en active Pending
- 2021-09-10 US US18/025,203 patent/US20240034812A1/en active Pending
- 2021-09-10 CN CN202180070059.6A patent/CN116472058A/zh active Pending
- 2021-09-10 JP JP2023515674A patent/JP2023541860A/ja active Pending
- 2021-09-10 IL IL301085A patent/IL301085A/en unknown
- 2021-12-21 US US17/558,430 patent/US11845805B2/en active Active
-
2023
- 2023-11-02 US US18/500,799 patent/US20240301078A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220119544A1 (en) | 2022-04-21 |
AU2021340232A1 (en) | 2023-04-13 |
CN116472058A (zh) | 2023-07-21 |
CA3192251A1 (en) | 2022-03-17 |
US11845805B2 (en) | 2023-12-19 |
EP4210747A1 (en) | 2023-07-19 |
US20240301078A1 (en) | 2024-09-12 |
BR112023004321A2 (pt) | 2023-04-04 |
IL301085A (en) | 2023-05-01 |
JP2023541860A (ja) | 2023-10-04 |
WO2022053654A1 (en) | 2022-03-17 |
MX2023002545A (es) | 2023-03-14 |
KR20230066583A (ko) | 2023-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11845805B2 (en) | Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma | |
US11608383B2 (en) | Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma | |
US11858995B2 (en) | Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia | |
US11535679B2 (en) | Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma | |
US11548952B2 (en) | Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma | |
US20230312759A1 (en) | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma | |
US20230303693A1 (en) | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma | |
US20230241211A1 (en) | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GENMAB A/S, DENMARK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:AHMADI, TAHAMTAN;BREIJ, ESTHER C.W.;CHIU, CHRISTOPHER W.L.;AND OTHERS;SIGNING DATES FROM 20220203 TO 20220310;REEL/FRAME:063014/0625 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |